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1. INTRODUCTION 
1.1. How cells sense their environment? 
 
Environment can be any biotic and abiotic surrounding of a living matter, 
which includes the factors that have an influence on its survival, development 
and evolution. For cells, the most important and challenging task is to couple 
the ever-changing environmental conditions with their own robust hereditary 
unit, gene. This gene-environment communication is manifested as an 
essential set of events necessary to maintain the cell as an entity, by 
promoting various biochemical processes and determining cellular physiology.   
In order to respond to the fluctuations in the environment, cells have created 
sophisticated communication channels, which receive, process, amplify and, 
in the end, respond to a variety of inputs by developing a regulatory 
mechanism responsible for changes in their physiology. These channels 
make a network of different proteins that respond to one input, providing 
specificity for each signal, but have intersection regions as well, enabling 
integration of diverse signals, resulting in various metabolic states of the cell.  
The start of all signaling cascades begins at the plasma membrane, where 
diverse signaling molecules, which are too big or too charged to enter to the 
cell, bind to receptors, causing its conformational change. This triggers the 
production of secondary messengers, which activate downstream protein 
kinases that can phosphorylate and activate further proteins involved in the 
cascade. In each of these events, the signal is amplified, and at some parts of 
the cascades, there are checkpoints responsible to either propagate or stop 
the signal from inducing some biochemical reaction. The “checkpoint” role is 
mostly visible in a subset of guanine nucleotide binding (G) proteins that have 
a major role in propagating the signal through various points in the cytoplasm 
until it reaches nucleus. These proteins act as a “molecular switch”, cycling 
from inactive, guanosine diphosphate (GDP)-bound to active, guanosine 
triphosphate (GTP)-bound state, depending on the input strength and 
availability.  
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They regulate numerous processes, most of them promoting activation of 
genes involved in cell growth, differentiation and survival. Mutations in these 
genes lead to over activation even in the absence of growth factors, and this 
aberrant signaling is one of the main reasons behind various pathological 
processes in organisms.  
The biggest group of small GTPases involved in signal transduction is Rat 
sarcoma (Ras) family. Apart from the regulation of guanine nucleotide binding, 
the function of these proteins is determined by their localization. The majority 
of them are associated with the lipid bilayers of plasma membrane or 
endomembranes due to their posttranslational modifications that additionally 
regulate protein-protein interactions and protect them from degradation 
(Konstantinopoulos, Karamouzis, and Papavassiliou 2007). 
The maintenance of this spatial segregation of small GTPases is necessary to 
keep the signaling cascade operative and responsive to inputs. All small 
GTPases have a tendency to localize to a certain locus in the cell, where they 
promote or stop the signal propagation, however, they undergo dynamic 
changes in their structure and localization in order to keep this steady state.  
This spatial cycle, therefore, keeps the number of entities (small GTPases in 
this case) in a system (cell) constant over time, but with their constant flux 
from one distinct location in the system to another (Vartak and Bastiaens 
2010). The spatial cycle of small GTPases in the cells is independent on their 
nucleotide bound state. However, due to its occurrence, the regulators of the 
activity state of the GTPase can act on it, thereby enabling biochemical 
processes to occur.  
In this thesis, I describe the spatial cycle of the small GTPase Ras homologue 
enriched in brain (Rheb), which relies on the phosphodiesterase 6D (PDEδ)- 
mediated solubilization in the cytosol, and its subsequent release on the 
perinuclear membranes through ADP ribosylation factor like 2 (Arl2)-GTP 
activity. Here, the spatial cycle is coupled to the GTPase cycle of Rheb, as 
TSC2 GTPase activating protein (GAP) activity on membranes regulates the 
level of GTP-hydrolysis on Rheb, while (re) solubilization by PDEδ is 
necessary for the new GTP-loading of Rheb. 
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1.1.1. Small GTPases and their role in signaling 
 
G-proteins are a protein class that transmits signal from various stimuli from 
cellular exterior to its interior by acting as a molecular switch. They can 
reversibly shift from ‘on’ to ‘off’ state, which is determined by their capacity to 
hydrolyze GTP to GDP (Vetter and Wittinghofer 2001) (Figure 1).  
G-proteins are divided into two groups: heterotrimeric G-protein complexes 
and monomeric small GTPases. Heterotrimeric G-proteins consist of alpha (α) 
and tightly associated beta (β) and gamma (γ) subunits. When a ligand in a 
form of growth factor, sugar, lipid or another protein activates G-protein 
coupled receptors (GPCRs), it promotes a conformational change that allows 
the GPCR to act as a guanine nucleotide exchange factor (GEF) for Gα, which 
dissociates from Gβγ and the GPCR.  Both Gα-GTP and Gβγ can now activate 
signaling cascades, while the GPCR can activate the next G-protein. Upon 
GTP-hydrolysis on Gα, the re-association with Gβγ occurs and the new cycle of 
activation can begin. Hydrolysis is enhanced by activity of regulator of G-
protein signaling proteins (RGSs), which act as GAPs for Gα subunits 
(Oldham and Hamm 2008). 
Small GTPases are homologous to the Gα subunit of heterotrimeric G-
proteins, but unlike Gα, which needs other two subunits in order to promote 
signaling events, they function independently as hydrolase enzymes (Biou 
and Cherfils 2004). In addition to GEFs and GAPs, the activity of small 
GTPases is regulated by guanosine nucleotide dissociation inhibitors (GDIs), 
which maintain small GTPases in inactive, GDP-bound state by stabilizing the 
inactive form and covering the lipid modification of the GTPase as a cytosolic 
complex (Seabra and Wasmeier 2004).  
Superfamily of Ras GTPases is the best-known group of small GTPases. 
They consist of more than 150 members, 20-25 kDa in size, divided into six 
families: Ras, Rho, Rab, Ran, Arf and Rad/Rem/Gem/Kir (RGK) GTPases. 
Each subfamily shares a conserved N-terminal G-domain, with two flexible 
regions (Switch I and Switch II) providing the nucleotide exchange activity, 
while the C-terminal part possesses features important for their subcellular 
localization, commonly modified with lipid posttranslational modifications such 
as myristoylation, palmitoylation and prenylation. These modifications allow 
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interaction with the phospholipids, and are responsible for membrane 
localization and GDI binding (Hancock et al. 1991; Hancock et al. 1989; 
Cox and Der 2002; Michaelson et al. 2005). 
Proteins from the Ras homologue (Rho) family are involved in a wide array of 
cellular processes, such as cytoskeletal reorganization, cell migration, 
transformation and metastasis. Ras-related nuclear protein (Ran) subfamily is 
necessary for nuclear transport of macromolecules and start of mitosis 
(Etienne-Manneville and Hall 2002). Ras-related in brain (Rab) proteins 
regulate the vesicular transport from various organelles as Golgi or ER to the 
plasma membrane, with each protein having an organelle-specific subcellular 
localization (Pereira-Leal and Seabra 2001; Zerial and McBride 2001). ADP 
ribozylation factor (Arf) subfamily consists of Arf and Arf-like proteins. They 
regulate vesicle trafficking and membrane fusion. This is the most diverse 
family of proteins in the entire group of small GTPases and in contrast to all 
the others, is not regulated by GDIs (Pasqualato, Renault, and Cherfils 
2002; Nie, Hirsch, and Randazzo 2003). RGK subfamily has various 
physiological functions such as controlling cardiac hypertrophy, inhibiting 
insulin-stimulated glucose uptake in myocyte and adipocyte cell lines, as well 
as inhibiting voltage dependent calcium channels (Correll et al. 2008). 
Members of Ras family of proteins have a prominent role in oncogenic 
transformation of the cells, with 15% of all human cancers having a point 
mutation in one of these proteins leading to their constitutive activation 
(Repasky, Chenette, and Der 2004). First characterized Ras proteins, 
Harvey and Kirsten rat-sarcoma (H- and K-Ras (alternatively spliced into two 
isoforms: K-Ras4A and K-Ras4B) were isolated from oncogenic viruses in 
rats: Harvey sarcoma and Kirsten sarcoma virus, and later found in human 
cells (Chang et al. 1982). Neuroblastioma rat-sarcoma (N-Ras) was identified 
in human neuroblastoma cells in 1980’s (Marshall, Hall, and Weiss 1982; 
Hall et al. 1983; Shimizu et al. 1983). All of these proteins are similar in 
structure and function, which is positively regulating proliferative processes. 
The process of guanine nucleotide exchange occurs on the N-terminal G 
domain, while the membrane localization is mediated by the C-terminal 
hypervariable region (HVR), which ends in common CAAX motif (C- cysteine, 
A-alyphatic amino acid, X-any amino acid)(Willumsen et al. 1984; Vetter and 
	 5	
Wittinghofer 2001). All three Ras proteins are enriched at the plasma 
membrane of the cell, through an active reaction-diffusion system (Schmick 
et al. 2014) that will be discussed in the following chapters. Presence of 
growth factors enhances Ras-mediated enrichment of its effector, rapidly 
accelerated fibroblastoma (Raf) kinase at the plasma membrane, which 
enables its phosphorylation and activation by several other protein kinases 
residing at the plasma membrane. This allows for further signal transduction 
to downstream effectors, such as extracellular signal-regulated kinase (Erk), 
resulting in cell proliferation (Nan et al. 2013). Rheb is another Ras-like 
protein, which shares significant homology with other members of the group, 
but differs in certain aspects as well. Opposite to Ras, Rheb is an 
endomembrane bound protein, residing mostly at the late 
endosomal/lysosomal structures (Sancak et al. 2008). It is a direct activator 
of mechanistic target of rapamycin (mTOR) kinase, which integrates various 
environmental cues in order to promote anabolic and inhibit catabolic cellular 
processes (Laplante and Sabatini 2012). Numerous pathways and inputs 
involved in the building up/breaking down processes in the cell must be well 
coordinated and balanced. Various pathways are involved in maintenance of 
the metabolic state of the cell, with mTOR complex 1 (mTORC1) signaling 
having a significant role.  
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Guanylate binding proteins constantly cycle from guanosine triphosphate (GTP) bound, active, state in which they 
promote signal propagation to guanosine diphosphate (GDP), inactive state, where the signal propagation is halted. 
The cycling from GDP to GTP state is mediated by guanosine nucleotide exchange factors (GEFs), whilst GTPase 
activating proteins (GAPs) mediate GTP-hydrolysis, resulting in inactivation.  
 
 
1.2. mTORC1 signaling 
1.2.1. Mechanistic target of rapamycin (mTOR) 
 
The serine/threonine kinase mTOR belongs to a family of phosphatidylinositol 
3- kinase-related kinases (PI3Ks) and is found in two distinct multiprotein 
complexes in the cell. Both mTORC1 and 2 regulate cell growth, proliferation, 
protein and lipid biosynthesis, while actin cytoskeleton is regulated by 
mTORC2 specifically (Wullschleger, Loewith, and Hall 2006; Guertin and 
Sabatini 2007; Laplante and Sabatini 2012).  
Yeast studies first identified FPR1 (yeast ortholog of FKBP12), TOR1 and 
TOR2 as the targets of rapamycin, and that mutation in each of their coding 
genes leads to rapamycin resistance (Heitman, Movva, and Hall 1991). 
Rapamycin is the antifungal substance isolated from the soil of Rapa Nui 
(Easter Island), coming from the bacterium Streptomyces hygroscopicus 
(Vezina, Kudelski, and Sehgal 1975). Originally, it was used as an 
immunosuppressant following organ transplantation, as it arrests T-
Figure 1. GTPase cycle of a G-protein 
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lymphocytes in mammals in G1 phase (Abraham and Wiederrecht 1996).  
In 1994, mTOR was found to be an ortholog of the yeast TOR1/2 proteins. 
Several groups described mTOR independently by using names as FKBP12–
rapamycin-associated protein (FRAP) (Brown et al. 1994), FKBP12 target 1 
(RAFT1) (Sabatini et al. 1994), rapamycin target 1 (RAPT1) (Chiu, Katz, and 
Berlin 1994) and sirolimus effector protein (SEP) (Chen et al. 1995). Due to 
ubiquitous expression of mTOR in various eukaryotic organisms, it was 
decided that ‘m’ would stand for ‘mechanistic’, not ‘mammalian’.  
As mentioned, there are two mTOR complexes in the cell, of which mTORC1 
is highly researched and well known. However, it is known that mTORC2 has 
a direct positive effect on protein kinase B (Akt) activation, by phosphorylating 
Akt at Ser 247; indicating its involvement in anabolism (Betz and Hall 2013). 
Additionally, it promotes cell motility and building of the actin cytoskeleton 
(Zhou and Huang 2011).  
mTORC1 and 2 share some of the subunits within the complex besides 
mTOR kinase. Those are mammalian lethal with SEC13 protein 8 (mLST8) 
and DEP domain-containing mTOR interacting protein (Deptor). mLST8 
interacts directly with mTOR and enhances its activity (Kim et al. 2003), while 
Deptor was found to have an inhibitory activity on mTOR within mTORC1.  
Additional components within mTORC2 are rapamycin insensitive companion 
of mTOR (Rictor), mammalian stress-activated protein kinase [SAPK]-
interacting protein (mSin1) and protein observed with Rictor (Protor) 
(Sarbassov et al. 2004; Frias et al. 2006) (Figure 2, right), all necessary for 
efficient activation of Akt at Ser 473. This might facilitate the phosphorylation 
of Akt on Thr 308 by phosphoinositide-dependent kinase 1 (PDK1), which is a 
prerequisite for full activation (Sarbassov et al. 2004; Sarbassov et al. 
2005). 
mTORC1, besides mTOR, mLST8 and Deptor is composed of two other 
subunits: regulatory-associated protein of mTOR (Raptor) and proline-rich Akt 
substrate of 40 kDa (PRAS40) (Kim et al. 2002; Sarbassov et al. 2005; Hay 
and Sonenberg 2004) (Figure 2, left). mLST8 not only interacts directly with 
mTOR and enhances its activity (Kim et al. 2003), but as well favors Raptor-
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mediated activation of the mTORC1 activity, by stabilizing mTOR-Raptor 
interaction (Hara et al. 2002; Kim et al. 2002; Schalm et al. 2003). These 
stimulative activities are balanced with negative regulators PRAS40 and 
Deptor. Activation of mTORC1, which occurs in response to nutrients and 
growth factors, results in phosphorylation of both PRAS40 and Deptor by 
mTORC1. This leads to dissociation of PRAS40 and Deptor from the complex 
and relieves the inhibitory constraint on its activity (Vander Haar et al. 2007; 
Peterson et al. 2009).  
The activation of mTORC1 is a consequence of converged signals on Rheb, 
which in a GTP-bound state can bind and activate mTORC1. This complex 
functions as a nutrient/energy/redox sensor and it responds to growth factors, 
hormones, nutrient, energy, oxygen and amino acid availability by promoting 
cell growth, protein and lipid biosynthesis, as well as ribosomal biogenesis. 
Two main activatory paths are involved in activation of mTORC1, both 
mediated by different GTPases, and that is growth factor signaling, dependent 
on Rheb and amino acid sensing, dependent on Ras-related (Rag) GTPases.  
 
	
Figure 2. Structure of mTOR complexes 
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 (adapted from: Guertin and Sabatini, 2009) 
The mTOR protein kinase is the catalytic core of two multiprotein complexes, mTORC1 and mTORC2. mTORC1 
(blue) additionally contains positive regulatory subunits called Raptor and mLST8 and two negative regulators, 
PRAS40 and Deptor. mTORC2 (purple) also contains mLST8 and the negative regulator Deptor as well as three 
positive regulatory subunits, Rictor, mSIN1 and Protor. Signaling events both upstream and downstream of mTORC1 
are a result of growth factor signaling via PI3K/Akt/TSC axis. mTORC2 role in signaling is not well known, other than 
the fact that by phosphorylating Akt it wires into the mTORC1 signaling. Role specific to mTORC2 is involvement in 
cell motility and cytoskeleton organization by acting on protein kinase C α (PKCα). Negative regulators of mTORC 
activities represented in red, positive regulators represented in green.  
 
1.2.2. mTORC1 regulation by growth factors 
Growth factors are one of the most important regulators of the mTORC1 
activity. Sensing of growth factor in the extracellular environment is crucial for 
keeping the cell growth, protein synthesis and other anabolic processes 
happening. The activation of mTORC1 via growth factors occurs through 
receptor tyrosine kinase/phosphoinositide 3-kinase/ protein kinase B 
(RTK/PI3K/Akt) signaling axis (Manning and Cantley 2007). Activation of 
PI3K can be accomplished through 3 different ways. One of them is by 
binding to activated Ras at the plasma membrane, which results in PI3K 
activation (Ong et al. 2001). Two other ways start with activation of receptors 
from a family of RTKs by an extracellular ligand. Two of the most prominent 
ligands activating mTORC1 are insulin and insulin-like growth factor 1 (IGF-1), 
which bind to their respective receptors, thereby activating them. This 
activation is manifested in dimerization of the monomers forming a receptor, 
and heterologous auto phosphorylation of the monomers. Tyrosine 
phosphorylation of insulin receptor substrate 1 (IRS-1) by insulin or IGF-1 
receptor is necessary for binding and activation of PI3K, as it introduces 
binding sites for proteins bearing Src homologue 2 (SH2) homology domain 
(Schlessinger 2002; Pawson 2002). Additionally, PI3K can bind directly to a 
phosphorylated RTK (Domchek et al. 1992). The active PI3K can migrate to 
inner side of the plasma membrane and phosphorylate phosphatidylinositol 
(4,5)-bisphosphate (PIP2) to create phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3). PIP3 can recruit Akt and the activation occurs by phosphorylation on 
Thr308 site by PDK-1. Akt is one of the most prominent proto-oncogenes with 
a lot of substrates. For example, it can bind to Bcl-2 associated X protein 
(BAX) and reduce its ability to form holes in mitochondrial membrane and 
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cause apoptosis (Cantley 2002). Additionally, active Akt causes ubiquitination 
of forkhead box protein O (FOXO) and its subsequent proteasomal 
degradation, thereby triggering cell proliferation (Zhang et al. 2011). But, one 
of the most important roles of Akt is inhibition of Rheb GAP, tuberous 
sclerosis complex (TSC), by phosphorylating subunit tuberin (TSC2) on Ser 
939 and Thr 1462. This results in relocalization of TSC to cytoplasm and 
guanine nucleotide exchange on Rheb. This active, GTP-bound Rheb can 
bind to and activate mTOR. The activation of numerous downstream 
effectors, such as ribosomal protein S6 kinase beta-1 (S6K-1) and ribosomal 
S6 protein (S6P), finally leads to protein synthesis (Ma and Blenis 2009) 
(Figure 3).  
As mentioned before, binding to the activated Ras GTPase can activate PI3K. 
Ras GTPase is activated by growth factors, cytokines, polypeptide hormones 
etc. and starts the signaling cascade that results in activation of Erk and 
promotes survival, cell proliferation and motility. The Ras-Erk and PI3K-mTOR 
signaling axis have some points of cross talk that end in either cross-
activation or cross inhibition. One of the main lanes for cross-activation is 
phosphorylation of TSC2 by Erk and its substrate, MAPK-activated protein 
kinase-1 (MAPKAP-K or p90rsk). The phosphorylation of TSC2 through Erk 
involves different sites compared to ones of Akt (discussed in detail in 1.3.2.), 
but the function is the same- to inhibit its GAP activity towards Rheb.  
The cross-inhibitory function involves strong IGF-1 stimulation where Akt 
phosphorylates inhibitory Raf sites in the N-terminus, thereby inhibiting Erk 
activation, but longterm, mTORC1 activation as well (Mendoza, Er, and 
Blenis 2011). 
The degree of activation of each axis depends on the various factors, such as 
amount and species of the growth factor and the balance of cross-reactivity 
processes. The role of the small GTPases (Ras and Rheb) are of high 
importance in order to propagate the signal. Activation of Rheb is the most 
important step in the activation of the mTOR signaling axis in general, as 
various upstream stimuli are all integrated in the tightly controlled TSC-Rheb 
relationship. 
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Figure 3. mTORC1 activation via growth factors 
Insulin/growth factor stimulation activates PI3-kinase (PI3K). PI3K catalyzes the conversion of PIP2 to PIP3, resulting 
in recruitment of Akt. Inactivation of phosphatase and tensin homolog (PTEN) and phosphorylation via PDK1 
activates Akt. Once Akt is activated, it directly phosphorylates TSC2 resulting in inactivation of TSC. Inactivation of 
the GAP TSC results in guanine nucleotide exchange on Rheb, which in GTP-bound state binds and activates 
mTORC1. mTORC1 further phosphorylates downstream effectors that promote protein synthesis and cell growth 
(ribosomal S6 kinase (S6K), eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1)), energy metabolism 
(hypoxia-inducible factor 1 α (HIF1α)) and adipogenesis (peroxisome proliferator-activated receptor γ (PPARγ)) and 
inhibit autophagy (autophagy related protein 13 (ATG13)). 
 
1.2.3. mTORC1 regulation by amino acids 
 
Investigations in rat muscles revealed that amino acids are necessary building 
blocks for protein synthesis (Preedy and Garlick 1986). Later research done 
in 2D cell culture revealed that a mixture of amino acids positively regulates 
mTORC1 signaling, while a combination of amino acids and growth factors is 
needed for phosphorylation of all downstream effectors (Hara et al. 1998; 
Wang et al. 1998). 
By regulating intracellular localization of mTORC1, amino acids regulate the 
signaling as well. When cells are deprived of amino acids, mTORC1 is located 
in the cytoplasm, whilst upon addition of amino acids it translocates to the 
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lysosomal surface, where it can be activated by Rheb (Sancak et al. 2008; 
Sancak et al. 2010) (Figure 4).  
Cell-reconstitutive assays suggested that amino acid sensing comes from the 
lysosomal lumen, where they accumulate after their extracellular addition 
(Zoncu et al. 2011). This particular stimulus sensing differs from the other 
activating paths, as it involves Rag GTPases. They were discovered as 
binding partners of Raptor through immunoprecipitation-mass spectrometry 
analysis and the screening of small GTPases using RNA interference (RNAi) 
in Drosophila melanogaster. Rag GTPases are obligate heterodimers 
consisting of functionally redundant Rag A/B and Rag C/D, localized at the 
lysosomal surface, where they recruit mTORC1 in amino acid dependent 
manner (Sancak et al. 2008).  
They do not rely on lipid modifications to tether them to membranes, but on a 
multiprotein complex Ragulator, which serves as a GEF for Rag A/B. 
Myristoylation and palmitoylation of Ragulator subunits tether Rag GTPases 
to the lysosome, and the Ragulator complex was reported to preferentially 
bind to nucleotide-free Rag A/B in vitro, which represents a classic GEF-
GTPase reaction. The Ragulator activity is regulated through amino acid 
dependent conformational changes mediated by lysosomal v-ATPase (Bar-
Peled et al. 2012). 
GAP activity towards Rags 1 (GATOR 1) is a subunit of GATOR complex and 
a GAP for Rag A/B, acting as a tumor suppressor and regulating their activity. 
Besides GATOR1, GATOR complex consists of GATOR2. GATOR2 has an 
inhibitory role towards GATOR1, and it is known that its activity is regulated 
through sestrins. Sestrins interact with GATOR2 in amino acid-dependent 
manner and have an inhibitory role toward mTORC1 (Chantranupong et al. 
2014). It was reported that they act as GDIs towards Rag A/B. Sestrin 
overexpression inhibits amino-acid-induced Rag guanine nucleotide exchange 
and mTORC1 translocation to the lysosome, while mutation of the conserved 
GDI motif creates a dominant-negative form of sestrin that renders mTORC1 
activation insensitive to amino acid deprivation (Peng, Yin, and Li 2014). 
While role of Rag A/B is well established, role of Rag C/D in the amino acid 
sensing is still relatively unknown. It is known, however, that in order to recruit 
mTORC1 from the cytoplasm to the lysosomes RagC/D, unlike Rag A/B, 
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needs to be GDP bound. This hydrolysis is regulated through folliculin, GAP 
for Rag C/D (Tsun et al. 2013).  
The role of TSC2 is crucial in growth factor signaling and mTORC1 regulation 
as it acts as a GAP for Rheb. However, recently it has been shown that it has 
a role in the amino acid sensing as well. Upon amino acid removal, Rag 
GTPases recruit TSC2 to the lysosome, where it can act on Rheb. It is 
necessary that both Rheb and Rag GTPases are fully inactive to relocalize 
mTORC1 to the cytoplasm from the lysosome. TSC2-null cells do not release 
mTORC1 fully from the lysosome, which results in constant propagation of the 
signal (Demetriades, Doumpas, and Teleman 2014). This suggests that 
TSC2 is a central protein in sensing cellular environment, and regulating the 
proper cellular response. 
 	
Figure 4. mTORC1 activation via amino acids 
Extracellular amino acids cross the plasma membrane to create an intracellular pool, which can activate mTORC1 
from lysosomal lumen. This results in conformational change of v-ATPase, which enables pentameric complex 
Ragulator to exert its function to Rag A and B GTPases. Active RagA/B recruits cytosolic mTORC1 to the lysosomal 
surface and releases lysosomal TSC, Rheb GAP, to the cytosol. This enables guanine nucleotide exchange on 
Rheb, which now, in GTP-bound state can bind to and activate mTOR at the lysosomal surface.  
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1.2.4. Small GTPase Rheb 
 
The small GTPase Rheb represents a unique protein within the Ras family. It 
shares several structural and functional characteristics with the other 
members of the group.  
There are two characterized Rheb proteins: Rheb and Rheb L1, with their 
respective genes localized on chromosome 7 (7q36) and 12 (12q13). Both 
Rheb genes share 51% amino acid identity (Gromov et al. 1995; Mizuki et 
al. 1996; Patel et al. 2003). Three main features characterize Rheb proteins: 
arginine (R) residue corresponding to glycine (G) at the position 12 for Ras 
proteins, conserved effector domain sequences and the C-terminal CAAX 
motif (C-cysteine, A-aliphatic amino acids, X-any amino acid, methionine (M) 
for Rheb), required for irreversible posttranslational modification, farnesylation 
(Urano et al. 2001).  
The work presented in this thesis focuses on the original protein, Rheb. Rheb 
is a 21-kDa protein, consisting of 184 amino acids. Almost all of them form the 
highly conserved G-domain, while the last C-terminal 20 amino acids form 
hypervariable region (HVR) ending in CAAX box (Yu et al. 2005). Rheb G-
domain contains G1-G5 boxes, features responsible for recognition of 
guanine ring and phosphates of guanine nucleotides (Bourne, Wrischnik, 
and Kenyon 1990). During GDP/GTP cycle, only switch I undergoes 
conformational change, while switch II remains stable, unlike switch II of other 
small GTPases. This process of GTP binding and hydrolysis is determining 
the protein activity and thereby, its function. The hydrolysis is facilitated by 
action of GAP TSC (discussed in section 1.3.2.). GEF is promoting GTP 
binding to small GTPases, thereby activating them. However, GEF for Rheb is 
still unknown. Due to high activation state of Rheb even in cells deprived of 
nutrients or growth factors, existence of GEF is suspicious (Inoki et al. 2003) 
(discussed in section 1.3.1.). 
The functional role of Rheb is activation of the mTORC1, which results in 
promotion of anabolic (protein synthesis, cell growth), and inhibition of 
catabolic processes (autophagy). mTORC1 is activated by various upstream 
stimuli, but the crucial event is binding to Rheb-GTP and activation, which is 
the bottleneck for all the inputs. 
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1.3. Regulation of Rheb activity 
 
The cycling of GTPases between active GTP-bound, regulated by GEFs, and 
inactive, GDP-bound state, regulated by GAPs, is necessary for them to exert 
their role as molecular switches and participate in the signaling cascades. 
GTP-hydrolysis is a rate-limiting step in proper regulation of activity of Ras 
GTPases. In hydrolysis, electronegative group is used for stabilization of 
hydrolytic water for nucleophillic attack of the γ-phosphate (Li and Zhang 
2004; Maegley, Admiraal, and Herschlag 1996). In Ras subfamily, the 
carboxyamide oxygen of Gln in switch II, stabilized by GAP activity, achieves 
this, while ‘arginine finger’ neutralizes developing negative charge on α- and 
β-phosphates of GTP. As all other small GTPases, Rheb has a low intrinsic 
GTPase activity, but the mechanism of GTP-hydrolysis differs than the one in 
other Ras isoforms.  
1.3.1. Positive regulation of Rheb  
 
Positive regulation of Rheb activity is largely unknown. It was reported that 
translationally controlled tumor protein (TCTP) acts as a putative GEF for 
Rheb in both Drosophila and human cell lines, as it directly associated with 
Rheb and displayed guanine nucleotide exchange activity with it in vitro and in 
vivo (Hsu et al. 2007). However, additional study disputed these results as it 
was found that no guanine nucleotide exchange activity of TCTP towards 
Rheb was detected in vitro, no direct interaction between Rheb and TCTP 
was detected by use of nuclear magnetic resonance (NMR) and depletion of 
TCTP showed no effect on activity of downstream effectors of Rheb 
(Rehmann et al. 2008). 
Unlike other Ras isoforms, Rheb has an auto-inhibited mechanism of GTP-
hydrolysis that involves Asp65 in switch II and Thr38 in switch I.  Hydrolysis is 
inhibited by Tyr35, which constrains active site conformation, restricting the 
access of catalytic Asp65 to the nucleotide-binding pocket. This inhibitory 
effect is lowered upon binding to GAP TSC2, whose ‘asparagine thumb’ 
(Asn1643) promotes catalysis in synergy with Asp65. Tyr35 is necessary to 
maintain responsiveness to growth factors and for regulation of the activity, as 
mutants cannot bind TSC2, but as well to keep Rheb in highly active state. 
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(Mazhab-Jafari et al. 2012).  
Rheb is usually found in high activation state in the cells; where more than 
20% of the protein is still found in GTP-bound state in serum-starved cells (Im 
et al. 2002). For other Ras proteins, this percentage in serum starvation 
conditions is around 0.5-8% (Satoh et al. 1990; Scheele, Rhee, and Boss 
1995). It was reported that Rheb has a higher affinity to bind GTP than GDP, 
and that this binding occurs preferably in solution, rather than bilayer 
membranes (Mazhab-Jafari et al. 2013). Additionally, cytosolic levels of GTP 
in cells are 10-fold higher than GDP (Ahearn et al. 2012), which would 
indicate that the guanine nucleotide exchange on Rheb does not require a 
positive regulator, but occurs rather spontaneously, in the absence or 
inhibition of negative regulator, TSC2.  
1.3.2. Tuberous sclerosis complex negatively regulates Rheb activity 	
TSC is a protein complex formed of 130-kDa hamartin (TSC1) and 200-kDa 
TSC2, and recently discovered 35 kDa Tre2-Bub2-Cdc16 1 domain family, 
member 7 (TBC1D7) (Dibble et al. 2012). The complex acts as a tumor 
suppressor by regulating activation of mTORC1 complex through integration 
of the environmental cues (energy, oxygen, stress levels) and availability of 
nutrients and growth factors. Abundance of growth factors leads to 
inactivation of the complex resulting in guanine nucleotide exchange on Rheb 
and mTORC1 activation (Huang and Manning 2008). 
The TSC1 gene is located at chromosome 9 (9q34) (van Slegtenhorst et al. 
1997), while TSC2 is on the chromosome 16 (16p13.3) (Kandt et al. 1992) 
and TBC1D7 on chromosome 6 (6p24.1). Defects in these genes result in a 
loss of control over cell growth and cause a disease called tuberous sclerosis 
complex (TSC). It is manifested in growth of benign tumors, seizures, 
developmental delay, skin abnormalities and lung and kidney disease 
(Northrup et al. 1993). The main function of the complex in the cell is its role 
as a GAP for small GTPase Rheb (Inoki et al. 2003; Tee et al. 2003). Only 
TSC2 possesses a GAP domain, unlike TSC1, which serves as a stabilizer of 
the complex, protecting TSC2 from ubiquitination and degradation 
(Benvenuto et al. 2000) and TBC1D7 stabilizes TSC1 dimerization (Qin et 
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al. 2016; Gai et al. 2016).  
The GAP activity of TSC2 increases the low intrinsic activity of Rheb. This 
results in GTP hydrolysis and inactivation of mTORC1, as the conformation of 
GDP-bound Rheb cannot activate mTORC1 (Patel et al. 2003; Inoki et al. 
2003; Tee et al. 2003).  
Besides Erk activated ribosomal S6 kinase (RSK), which inactivates TSC2 by 
phosphorylating it at Ser 1798, the main regulator of TSC2 GAP activity is Akt. 
This was the first kinase demonstrated to phosphorylate TSC2 at Ser 939 and 
Thr 1462, thereby inactivating it. However, the molecular mechanism 
underlying this event is still largely unknown. One of the hypotheses suggests 
that the disruption of TSC is responsible for its inactivation, as the insulin 
stimulation promotes Akt phosphorylation-dependent TSC dissociation in 
Drosophila Schneider 2 (S2) cells (Potter, Pedraza, and Xu 2002). This has 
been disproven, as another study did not detect any effect on TSC complex 
integrity upon insulin stimulation and Akt activation (Manning et al. 2002; 
Inoki et al. 2002).  
The last hypothesis suggested that the TSC2 GAP activity is spatially 
regulated. Subcellular fractionation revealed that TSC2 levels are elevated in 
the cytosol after insulin stimulation, whereas Rheb and TSC1 were exclusively 
found in the membrane fraction, and their levels remained unchanged, 
regardless of the growth factor stimulation. From these findings, it was 
concluded that phosphorylation of TSC2 by Akt triggers the release of TSC2 
from TSC1, thereby changing its localization, resulting in impaired TSC2 GAP 
activity towards Rheb (Menon et al. 2014; Demetriades, Doumpas, and 
Teleman 2014). 
Additional studies have proven that the mechanism of TSC2 activity is indeed 
spatially regulated. In cells deprived of nutrients and growth factors, TSC2 
showed high perinuclear localization, co-localizing with the lysosomal marker 
lysosome-associated membrane protein 2 (LAMP2). In amino acid starved 
condition, TSC is recruited to the lysosomal surface via the activity of Rag 
GTPases. Upon stimulation with both nutrients and amino acids, TSC2 has a 
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diffuse, cytosolic pattern and does not associate with lysosomal membranes, 
abolishing the negative effect of it on mTORC1 activation (Demetriades, 
Doumpas, and Teleman 2014; Demetriades, Plescher, and Teleman 2016; 
Menon et al. 2014).    
Besides Akt, the main negative regulator of TSC2, there are several upstream 
positive regulators of its activity. The activating role of AMPK and HIFα to 
TSC is a result of low energy and oxygen levels, respectively. AMPK 
phosphorylates TSC2 ant Thr 1227 and Ser 1345 (Inoki et al. 2003; Shaw et 
al. 2004), while HIFα induces REDD1 to neutralize AKT dependent inhibition 
of TSC2 (DeYoung et al. 2008). 
Altogether, TSC serves as a bottleneck for the variety of upstream stimuli 
sensed by mTORC1. Its role as a negative regulator for Rheb acts as a final 
checkpoint before the cell decides to promote anabolic processes as cell 
growth, protein synthesis or inhibition of autophagy.  
 
1.4. Localization is necessary for function of small GTPases 
 
Ras protein can be divided into three separate parts. First one, N-terminal 
conserved G-domain determines activity state of the protein. It is similar 
amongst all members of the superfamily, and it possesses motifs necessary 
for guanine nucleotide binding. Second part is HVR, representing last 20 C-
terminal amino acids. This part possesses several features determining 
localization of the protein, and highly varies from one member to another. At 
the C-terminal end, the third part, -CAAX box serves as a substrate for 
posttranslational modification, prenylation (Lowy and Willumsen 1993). 
Depending on the X in the CAAX box, either a farnesyl or a geranylgeranyl 
group is added. Enzyme farnesyltransferase recognizes methionine (M), 
serine (S), glutamine (Q), alanine (A) or cysteine (C), while 
geranylgeranyltransferase I recognizes leucine (L) or glutamate (E) (Maurer-
Stroh and Eisenhaber 2005; Taylor et al. 2003). Additionally, three C-
terminal amino acids (-AAX) are removed by RAS converting enzyme 1 
(RCE1) and isoprenylcysteine o-methyltransferase methyl esterifies the 
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carboxyl group of prenylated cysteine (Winter-Vann and Casey 2005). 
Farnesylation, which occurs in Ras proteins, mediates protein-protein 
interactions and increases association of these proteins with membranes  
H-, N- and K-Ras have additional localization feature(s) immediately upstream 
of farnesylated cysteine. In N- and H-Ras, the second signals are one or two 
palmitoylated cysteins, immediately upstream of the –CAAX box, respectively 
(Figure 5., 1st and 2nd row). K-Ras relies on polybasic stretch consisting of 9 
positively charged lysines (Figure 5., 3rd row), which electrostatically interact 
with negatively charged phospholipids in the inner leaflet of the plasma 
membrane of the cell. Rheb lacks any of these features in the HVR, which has 
a net neutral charge (Figure 5., 4th row); therefore, its localization relies 
solely on farnesylation (Hancock et al. 1989; Hancock et al. 1991; Rocks et 
al. 2010; Michaelson et al. 2005; Schmick et al. 2014). This is why Rheb is 
associated with all endomembranes of the cell, and significant plasma 
membrane enrichment, visible for other Ras proteins, is lacking. It was 
reported that farnesylation of Rheb is required for full activation of mTOR in 
vivo, as the non-farnesylated mutant (-SAAX) was not able to induce S6K 
phosphorylation (Hanker et al. 2010). 
Since many of Ras proteins are involved in oncogenic transformation of the 
cells, a lot of therapeutical approaches rely on targeting prenylation enzymes, 
thereby disrupting their subcellular localization. It was reported that 
phosphodiesterase 6D (PDEδ) is necessary in maintaining localization of 
prenylated Ras proteins, as its knockdown resulted in relocalization of 
plasma-membrane Ras proteins to membranes in the cell (Chandra et al. 
2012; Zimmermann et al. 2013; Schmick et al. 2014). The role of 
solubilizing factor maintaining membrane localization is counterintuitive, 
however, solubilization is one in the chain of events necessary for proper 
localization of Ras proteins, forming a mechanism that will be discussed in the 
following chapters. 
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Figure 5. Hypervariable region (HVR) of Ras proteins mediates their membrane localization (based on (Bar-
Sagi 2001) 
Ras proteins are on average up to 189 amino acids long. N-terminal end consists of catalytic subunit- G domain, 
responsible for binding of guanine nucleotides and activity state of the GTPase. Last C-terminal 20 amino acids form 
hypervariable domain (HVR) that possesses features responsible for localization of the protein. All Ras proteins (H-, 
N-, K-Ras and Rheb) end in a common –CAAX motif, where the last cysteine undergoes irreversible posttranslational 
modification, farnesylation (in red), while the last three amino acids are methylated (OMe). H-Ras and N-Ras 
undergo additional reversible modification, palmitoylation, on either two (H-Ras) or one (N-Ras) cysteines in HVR. 
This increases their hydrophobicity, and they mostly associate with plasma membrane of the cell. K-Ras has a 
polybasic stretch consisting of multiple lysines (K) which through electrostatic interaction associate with negatively 
charged lipid bilayer of the plasma membrane. Rheb is solely farnesylated protein, with a net neutral charge in the 
HVR, therefore it associates mostly with endomembranes of the cell.  
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1.4.1. The GDI-like solubilization factor PDEδ prevents equilibration of 
prenylated Ras proteins on endomembranes 	
PDEδ has been identified as the fourth subunit of rod-specific cGMP 
phosphodiesterase, PDE6 (Gillespie et al. 1989; Florio, Prusti, and Beavo 
1996). Holoenzyme PDE 6 is a heterodimer made of PDEα and PDEβ, 
regulated by two inhibitory γ subunits (Gillespie et al. 1989). Prenylation 
allows both PDEα and PDEβ to associate with membranes, with PDEα 
undergoing farnesylation and PDEβ geranylgeranylation (Qin, Pittler, and 
Baehr 1992). On the other hand, PDEδ is found exclusively in the soluble, 
cytosolic fraction of the cell. It was shown that PDEδ binds to the prenylated 
C-terminus of PDEα and β, resulting in a translocation of the holoenzyme 
PDE6 from membranes to cytosol (Florio, Prusti, and Beavo 1996). The 
specific residues on the inner surface of the lipid-binding pocket are identical 
to the ones from Rho GDIs. These proteins sequester and bury the lipid 
moiety (DerMardirossian and Bokoch 2005; Goody, Rak, and Alexandrov 
2005). The core domain of PDEδ is made of an immunoglobulin-like β-
sandwich fold with two β-sheets, followed by an N-terminal α-helix (Hanzal-
Bayer et al. 2002). However, it lacks the N-terminal helix-loop-helix motif, 
which allows for interaction with the G domain of GTPases (position of the 
switch regions), which indicates that PDEδ binds the C-terminal part of 
GTPases, and that this interaction is nucleotide-independent (Nancy et al. 
2002; Hanzal-Bayer et al. 2002). Additionally, PDEδ was identified as a 
solubilizer for prenylated proteins, with a stronger preference to farnesyl, 
rather that geranylgeranyl moiety, although it was reported to solubilize small 
GTPase Rab 13 (Marzesco et al. 1998). The similarity of the three-
dimensional structure to Rho-GDI and all the described findings combined, 
established PDEδ as a GDI-like solubilizing factor for prenylated proteins, with 
a role similar to the Rho GDIs. 
PDEδ has been shown to have an essential role in maintaining spatial 
organization of K-, N- and H-Ras proteins. Due to spontaneous dissociation 
from the membranes and endocytosis, these plasma membrane-bound 
proteins are internalized. By passively sequestering these proteins in the 
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cytosol, PDEδ enhances their effective diffusion speed and allows for faster 
exploration of the interior of the cell. The formation of PDEδ-Ras complex is 
necessary to counter the entropic tendencies arising from the structure of Ras 
proteins. As farnesylated proteins, they associate with any membrane in the 
cell, and in the absence of PDEδ, they tend to equilibrate to abundant surface 
of the endomembranes, resulting not only in mislocalization from the plasma 
membrane, but as well in their impaired signaling activity (Chandra et al. 
2012; Zimmermann et al. 2013; Schmick et al. 2014). In addition to 
prenylated Ras proteins, PDEδ binds two small GTPases, Arl2 and Arl3 in a 
lipid independent, but nucleotide dependent manner, and serves as the 
effector for these two GTPases (Hanzal-Bayer et al. 2002). The fast diffusion 
of PDEδ-Ras complex in the cell enhances the speed of encountering 
perinuclear region of the cell. In this particular region, small GTPase Arl2 is 
active, GTP-bound and can bind to PDEδ. If it binds, this will result in a 
“closed” conformation of PDEδ, and displacement of farnesylated cargo 
(Ismail et al. 2011; Schmick et al. 2014). This event is essential for 
maintaining the localization of the Ras proteins, including Rheb. Arl2-Gpp-
NHp and Arl2-GDP in complex with PDEδ and F-Rheb showed that PDEδ 
conformation is different in either of them. When bound to Arl2-GDP the 
hydrophobic pocket is open, resulting in a cavity of 581 Å and this 
conformation is called open conformation. In complex with Arl2-GTP, residues 
of PDEδ's hydrophobic pocket such as Met20, Ile129 and Arg61 are shifted 
toward the inside of the pocket and clash with the farnesyl group, and this 
conformation is called closed conformation (Figure 6.). To see how this 
PDEδ-Arl2-GTP interaction clashes with PDEδ-Rheb interaction, fluorescence 
correlation spectroscopy (FCS) with Rheb and PDEδ was done in cells. When 
Arl2GppNhp was added, the soluble fraction of Rheb was decreased, unlike 
when Arl2-GDP was added. This was confirmed with fluorescence 
polarization experiments as well. This showed that PDEδ in closed 
conformation cannot bind farnesyl group of Ras proteins and that Arl2 only in 
GTP-bound state can displace this cargo (Ismail et al. 2011). This placed 
Arl2 to have a role of GDI-displacement factor (GDF), a class of protein that 
unloads Rab and Rho proteins from their cognate GDI’s to their respective 
destinations (Dirac-Svejstrup et al. 2000; DerMardirossian and Bokoch 
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2005; Dransart et al. 2005; Goody, Rak, and Alexandrov 2005).  
 
Figure 6. Mechanism of allosteric release of farnesylated cargo from PDEδ (adapted from: Ismail et al., 2011) 
(a) Superimposition of F-Rheb–PDEδ, on the PDEδ–Arl2-GTP complex with PDEδ in cyan and Arl2 in yellow and 
switches in purple. Right-hand side shows an enlargement, with a rotation of ∼180° along the y-axis, of the two 
PDEδ conformations highlighting the conformational change involving movements of beta sheets. PDEδ amino acid 
residues shifting to closed conformation highlighted in the image. (b) Hydrophobic pocket of PDEδ and F-cysteine in 
the closed (left) and open (right) conformation, with farnesyl (blue) modeled into the Arl2 complex, shown as 
electrostatic surface presentation.  
1.4.2. The PDEδ-Arl2 mediated spatial cycle maintains localization of 
prenylated Ras proteins  	
The hypervariable region of the Ras family of proteins is a crucial factor in 
determining their localization. All of these proteins undergo irreversible 
farnesylation in the CAAX box, enhancing their affinity for membranes. 
However, there are some different features in the HVR that target Ras 
proteins to specific membrane compartments. Although all of the proteins are 
subjected to a spatial cycle mediated by PDEδ and Arl2-GTP, their HVR 
features determine their steady state localization. 
1.4.2.1. K-Ras spatial cycle 
K-Ras possesses polybasic stretch consisting of 10 lysines in the HVR. The 
inner leaflet of phospholipids at the plasma membrane is negatively charged, 
therefore electrostatic interaction, combined with farnesylation localizes it at 
the plasma membrane of the cell. However, due to endocytic processes, but 
as well spontaneous dissociation of the protein itself from the plasma 
membrane (fulltime 8 min), K-Ras is eventually internalized and lost from the 
plasma membrane on the abundant surface of endomembranes (Schmick et 
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al. 2014). During endocytosis, plasma membrane undergoes through changes 
in the curvature. The positive (convex) curvature is imposed on inner leaflet of 
the plasma membrane during the formation of the vesicle, while the outer 
leaflet is negatively (concave) curved and borders lumen of the vesicle. The 
change in curvature is accompanied with the functional changes as well. It 
was observed that the phosphoinositide composition decreases upon 
membrane scission and that phosphatidinyl serine is excluded from the 
endosomes. Therefore, this net loss of negative charge will result in different 
association/dissociation rates to/from the proteins bound to them (McMahon 
and Boucrot 2015; Sigismund et al. 2012). As endomembranes have an 
overwhelming surface area (200x more) compared to plasma membrane, 
internalized K-Ras will have a tendency to equilibrate on them inside the cell. 
However, the partitioning of K-Ras from endomembranes to cytosol is 2:1, 
unlike plasma membrane-endomembrane, which is 10:1. Therefore, once 
internalized majority of K-Ras will be found in the cytosol. Here, PDEδ 
passively sequesters it by binding to the farnesyl moiety, thereby enhancing 
its effective diffusion. It was shown that PDEδ is essential for localization of 
KRas, as the knockdown of it results in equilibration of K-Ras to all 
membranes. This paradox of passive solubilizing activity contributing to 
localization points to the existence of the energy-driven, additional component 
in this spatial cycle of K-Ras. The energy is provided in a form of small 
GTPase Arl2 (Ismail et al. 2011). This protein is active, GTP-bound in the 
perinuclear area of the cell. In its active form, it binds to PDEδ, causing an 
allosteric change resulting in displacement of the farnesylated cargo, allowing 
it to bind to membranes again. In this cellular region, recycling endosome, 
negatively charged on its cytoplasmic leaflet, serves as an electrostatic trap 
for K-Ras released from PDEδ via Arl2 activity. Fluorescence recovery after 
photobleaching (FRAP) experiments with mCitrine K-Ras and mTFP Arl2 wt 
or constitutively active form, Arl2 Q70L, showed that this recovery is normal 
and complete only with wt-form present, rather than constitutively active Arl2 
Q70L, showing that this release mechanism indeed must be local otherwise 
the whole cycle would not be efficient. In the perinuclear area, recycling 
endosome-associated K-Ras is transported back to the plasma membrane via 
vesicular recycling (Schmick et al. 2014; Schmick, Kraemer, and 
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Bastiaens 2015) (Figure 7, left). 
1.4.2.2. Acylation cycle H-Ras and N-Ras 	
H-Ras and N-Ras undergo additional lipidation on the two cysteins in their 
HVR. This reversible modification, palmitoylation, together with irreversible, 
farnesylation, makes a protein more hydrophobic and more susceptible to 
localize to plasma membrane of the cell. The non-palmitoylated mutant of H-
Ras, H-Ras C181/184S, therefore localizes to endomembranes (Misaki et al. 
2010). The cycles of depalmitoylation and palmitoylation are essential to 
counter endocytosis and spontaneous dissociation of the proteins, which 
would cause equilibration of H- and N-Ras on the endomembranes. The 
activity of acyl protein thioesterases (APTs) in the cytoplasm removes the 
palmitoyl moiety, reducing hydrophobicity and causing H- or N-Ras to partition 
between endomembranes and cytosol. In the cytosol, now solely farnesylated 
H- and N-Ras, are sequestered by farnesyl binding to hydrophobic pocket of 
PDEδ. This complex has a very high effective diffusion throughout the cell. 
Perinuclear activity of Arl2 GTPase releases it from PDEδ, enabling 
association with the membranes in this area. Additional localized activity of 
palmitoyltransferases (PATs) at the Golgi results in repalmitoylation and 
concentration of H- and N-Ras at this organelle. Both the H- and N-Ras then 
can be recycled to the plasma membrane by directed vesicular transport from 
the Golgi apparatus (Figure 7, middle).  
Unlike H-Ras, which possesses two cysteins in the HVR and undergoes 
double palmitoylation, N-Ras has only one (Rocks et al. 2010). This makes it 
less hydrophobic compared to H-Ras, and at the steady state, in addition to 
plasma membrane, it is found in the interior of the cell, where, in the cytosol, it 
can bind to PDEδ. Additionally, since it loses the only palmitoyl moiety due to 
APT activity in the cytoplasm, it is always free to bind to PDEδ, and be 
released in the perinuclear area of the cell. Here, PATs can repalmitoylate 
and it can be recycled to the plasma membrane. This results in higher Golgi 
localization of N-Ras compared to H-Ras. As H-Ras is more hydrophobic, the 
spontaneous dissociation from the plasma membrane is slower compared to 
N-Ras, therefore, at the steady state, it is mostly found at the plasma 
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membrane with a very small fraction at the Golgi apparatus (Vartak et al. 
2014).  
1.4.2.3. Rheb spatial cycle   
 
 Farnesylation, together with additional membrane targeting motifs associates 
Ras proteins to membranes (Welman, Burger, and Hagmann 2000). As 
mentioned previously, K-, H- and N-Ras possess additional targeting features 
that enable association with the plasma membrane. Rheb, however, lacks any 
of these additional targeting features in the HVR, and is solely farnesylated 
(Hancock, Paterson, and Marshall 1990). Therefore, Rheb associates with 
the abundant surface of the endomembranes, rather than the plasma 
membrane exclusively.  This was proven by changing Rheb HVR with H-Ras 
HVR, resulting in plasma membrane localization of Rheb (Takahashi et al. 
2005).  
Besides associating with the endomembranes, Rheb distinctly concentrates in 
the perinuclear region of the cell. Co-localization with Rab 7 and LAMP2 
placed it at the late endosomal/lysosomal structures (Sancak et al. 2008). 
However, the correct mechanism of maintaining the localization of this protein 
is still unknown. It was shown that Rheb interacts with PDEδ and due to high 
spontaneous dissociation rate from the membranes, upon ectopic expression 
of PDEδ displays homogenous fluorescence intensity pattern in the cell. 
Additionally, it was corroborated that the Arl2-GTP-mediated release 
mechanism of farnesylated cargo from PDEδ was corroborated to occur in the 
perinuclear region of the cell (Schmick et al. 2014). Based on these 
observations, Rheb served as a candidate for PDEδ/Arl2-GTP system for 
maintainance of localization of prenylated Ras proteins. Due to its structure 
and the lack of secondary membrane-targeting feature, it dissociates faster 
(compared to K-, N- and H-Ras) from membranes to the cytosol. Here it is 
solubilized by PDEδ, and once the complex reaches perinuclear area, Arl2-
GTP activity displaces it from PDEδ onto these membranes (Schmick, 
Kraemer, and Bastiaens 2015) (Figure 7, right).  
In this thesis, we demonstrate that the PDEδ/Arl2-GTP driven spatial cycle is 
coupled to a GTPase cycle of Rheb. In this cycle, Rheb-GTP associates with 
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PDEδ in the cytosol, and through localized Arl2-GTP activity is displaced and 
concentrated onto perinuclear membranes. This drives its interaction with 
mTOR and its subsequent activation. In the absence of growth factors, 
perinuclear TSC2 activity promotes rapid GTP-hydrolysis on Rheb. This 
loosens Rheb-mTOR, interaction, resulting in enhanced dissociation of Rheb-
GDP from perinuclear membranes and its resolubilization by PDEδ. Excess of 
GTP in the cytoplasm of cells (Ahearn et al. 2012), together with the higher 
GTP-binding affinity of Rheb (Patel et al. 2003; Im et al. 2002; Tabancay et 
al. 2003) and the lack of GAP activity in the cytosol (Demetriades, Doumpas, 
and Teleman 2014; Demetriades, Plescher, and Teleman 2016; Menon et 
al. 2014), causes efficient GDP/GTP exchange on soluble Rheb, switching it 
back into an active state. Growth factor stimuli (e.g. insulin) inactivate the 
GAP TSC2; effectively stopping the PDEδ/Arl2-GTP mediated spatial cycle by 
tight association of Rheb-GTP with mTORC1, which is not anymore available 
for (re) solubilization by PDEδ. The PDEδ/Arl2-GTP spatial cycle thus 
enhances responsiveness to growth factors by providing an energy-driven 
mechanism for the enrichment of Rheb-GTP on perinuclear membranes that 
thermodynamically favors its interaction with mTORC1. 
 
 
Figure 7. Spatial cycles of prenylated Ras proteins  (adapted from Schmick et al., 2015) 
 
Due to spontaneous dissociation and processes such as endocytosis prenylated Ras proteins are displaced from the 
plasma membrane to the interior of the cell. Due to the farnesyl moiety in the HVR, they have a tendency to 
equilibrate to the abundant surface of the endomembranes. Upon dissociation from the membranes, KRas4B (green) 
is solubilized by binding to PDEδ. Once the complex reaches perinuclear area of the cell, Arl2-GTP binds to PDEδ, 
causing a conformational change resulting in displacement of KRas4B on perinuclear membranes. Here, negatively 
charged recycling endosome (RE) serves as an electrostatic trap for released KRas4B, which upon association with 
RE is transported to the plasma membrane of the cell. Upon dissociation from the plasma membrane, palmitoyl 
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moiety is cleaved from HRas (blue) via activity of acyl protein thyoesterases (APT1/2). This enables HRas to bind to 
PDEδ and once th complex reaches perinuclear area to be displaced by Arl2-GTP activity. Here, it associates with 
Golgi apparatus, where palmitoyltransferases re-palmitoylate HRas, which is then via vesicular transport recycled to 
the plasma membrane. As a solely farnesylated protein, Rheb (red) has a high partitioning rate from the 
endomembranes to the cytosol. In the cytosol, it is solubilized by PDEδ. Once the complex reaches the perinuclear 
area of the cell, Rheb is displaced from PDEδ via Arl2-GTP activity, maintaining its out-of-equilibrium enrichment at 
the perinuclear membranes of the cell.  
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1.5. Objectives 
 
The main aim of this thesis was to determine whether Rheb localization is 
mediated by spatial cycle involving PDEδ/Arl2 system. Additionally, how this 
spatial cycle regulates subcellular Rheb localization and what are the 
implications on the signaling output of Rheb? The final question was to 
resolve whether the activity of Rheb has any effect on its localization, and in 
the end, what are the implications on cell physiology, which could arise as a 
consequence of this crosstalk? 
In order to answer this, we have applied the previous knowledge known of the 
PDEδ/Arl2 spatial cycle and resolved how this mechanism is involved in 
maintenance of Rheb localization in the cell. Additionally, we have 
experimentally resolved cellular locus of PDEδ/Arl2 interaction, which, 
combined with previous knowledge, resulted in understanding how this 
release mechanism maintains localization of all prenylated Ras proteins.  
We used cells with constitutively active Rheb to examine whether GTPase 
and spatial cycle are coupled and what are the implications of this coupling on 
signal propagation and processes regulated by Rheb/mTORC1. 
This thesis is divided in four parts. The first part focuses on concept of cell-
environmental communication and represents an overview of current 
knowledge on spatial cycles, regulation of Rheb activity and characteristics of 
the protein family it belongs to.   
The second part covers methods that were used in order to resolve the 
mentioned questions, and overview of Crispr-CAS method for gene editing 
and FRET-FLIM, both used in different experimental setups. 
The third part presents results obtained during the work, and the final part 
discusses the results and based on them, presents the model of coupling of 
GTPase and spatial cycle of Rheb.  
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals 	
Acetic acid      Baker 
30 % Acrylamide/Bis solution    Bio-Rad laboratories, Inc 
Ammonium persulfate (APS)      SERVAElectrophoresis GmbH 
Bromophenolblue     Sigma Aldrich® 
Complete Mini EDTA-free protease  
inhibitor tablets     Roche Applied Science 
Crystal Violet      Life Science 
2´-deoxyadenosine-5´-triphosphate (dATP) Invitrogen™ Life Technologies 
2´-deoxythymidine-5´-triphosphate (dTTP) Invitrogen™ Life Technologies 
2´-deoxycitosine-5´-triphosphate (dCTP)  Invitrogen™ Life Technologies 
2´-deoxyguanosine-5´-triphosphate (dATP) Invitrogen™ Life Technologies 
Dimethyl sulfoxyde (DMSO)   SERVAElectrophoresis GmbH 
Disodium hydrogen phosphate (Na2HPO4) Merck KG 
Ethanol       J.T.Baker 
Ethydium Bromide (EtBr) (10mg/mL)  Fisher Scientific 
Ethylene diamine tetracetic acid (EDTA)  Fluka® Analytical 
Ethylene glycol tetraacetic acid (EGTA)  Life Science 
Glycerol      Gerbu Biotechnik GmbH 
Glycine       Carl Roth GmbH 
Roti®-Histofix 4%     Carl Roth GmbH 
Hoechst 33258     Sigma 
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IGEPAL® CA-630     Sigma Aldrich® 
Kanamycin sulfate      Gerbu Biotechnik GmbH 
Magnesium chloride (MgCl2)   Merck KG  
Methanol       AppliChem GmbH 
2-Mercaptoethanol     SERVAElectrophoresis GmbH 
Monopotassium phosphate (KH2PO4)  J.T.Baker 
Paraformaldehyde     Fluka 
Phosphatase Inhibitor Cocktail 2   Sigma Aldrich® 
Phosphatase Inhibitor Cocktail 3   Sigma Aldrich® 
Potassium chloride (KCL)    J.T. Baker 
Sodium chloride (NaCl)    SERVAElectrophoresis GmbH 
Sodium deoxycholate (NaDOC)   Sigma Aldrich® 
Sodium dodecyl sulfate    Carl Roth GmbH 
Sodium pyrophosphate (Na4O7P2)  J.T. Baker 
N,N,N’,N’-Tetramethylene-diamine (TEMED) Sigma Aldrich® 
Tris-Base       Carl Roth GmbH 
Tris-HCl      J.T. Baker 
Triton X-1000     SERVAElectrophoresis GmbH 
Tween 20      SERVAElectrophoresis GmbH 
Ultra-Pure™ Agarose    Invitrogen™ Life Technologies 
Xylen cyanole     Sigma 
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2.1.2. Enzymes and proteins 
 
AccuPrime™ Pfx DNA polymerase  Invitrogen™ Life Technologies 
Age-I-HF (10 000 U/mL)    New England Biolabs Inc. 
BamHI (20 000 U/mL)    New England Biolabs Inc. 
Bovine Serum Albumine (BSA)   New England Biolabs Inc. 
BsrGI (20 000 U/mL)    New England Biolabs Inc. 
Calf Intestinal Phosphatase (10 000 U/mL) New England Biolabs Inc. 
DpnI       New England Biolabs Inc. 
EcoRI-HF      New England Biolabs Inc. 
FastDigest BbsI (BpiI) #FD1014   Fermentas/Thermo Scientific 
Insulin solution human (I9278)   Sigma Aldrich® 
PfuUltra High-fidelity DNA polymerase AD Stratagene 
PlasmidSafe ATP-dependent DNase #E3101K Epicentre 
T4 DNA-ligase #15224-017   Invitrogen™ Life Technologies 
T4 polynucleotide kinase #M0201S  New England BioLabs 
T7 DNA ligase #L602L    Enzymatics 
2.1.3. Plasmids 	
mCherry-N1     Clontech Laboratories Inc. 
mCitrine-N1     Clontech Laboratories Inc. 
mTFP-N1     Clontech Laboratories Inc. 
mCherry-Arl2 wt generated by inserting cDNA 
encoding for human Arl2 to mCherry-
N1 vector. 
mCherry-Arl2 Q70L generated by inserting cDNA 
encoding for human Arl2 to mCherry-
N1 vector, then mutating glutamine 
(Q) at position 70 to leucine (L) to 
generate constitutively active mutant. 
mCherry-PDEδ generated by inserting cDNA 
encoding for human PDE6δ to 
mCherry-N1 vector. 
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mCherry-Rheb generated by inserting cDNA 
encoding for human Rheb1 to 
mCherry-N1 vector. 
 
mCitrine-Rheb generated by inserting cDNA 
encoding for human Rheb1 to 
mCitrine-N1 vector. 
mCitrine-Rheb HVR generated by inserting cDNA 
encoding for hypervariable region 
(HVR) with CAAX-box of human 
Rheb1 to mCitrine-N1 vector. 
mTFP-Arl2 wt generated by inserting cDNA 
encoding for human Arl2 to mTFP-
N1 vector. 
mTFP-Arl2 Q70L generated by inserting cDNA 
encoding for human Arl2 to mTFP-
N1 vector, then mutating glutamine 
(Q) at position 70 to leucine (L) to 
generate constitutively active mutant. 
Psp-Cas9-E (BB)-2A-puro #48139 Addgene 
 
2.1.4. Oligonucleotides 	
1) 
3’ctcagatctcgagccaggataattttggaggcagaaaaaatggacggggcagcttcacaaggcaag
tcttcatgctcggtgatgtgagaattctgcagtcga 5’ (Rheb-HVR with overhang in bold) 
2) 3’ctcagatctcgagccaggataat 5’ (FW primer for mCitrine-RhebHVR) 
3) 5’ gactgcagaattctcacatcacc 3’ (REV primer for mCitrine-RhebHVR) 
4)  3’-CACCATCCCTGGCCCGCTCGTCCT-5’ (FW primer for sgRNA PDEδ) 
5) 5’-AAACAGGACGAGCGGGCCAGGGAT-3’ (REV primer for sgRNA 
PDEδ) 
6) 3’-catggtcctgctggagttcgtg-5’ (sequencing FW primer for pECFP-C1 vector 
(Clontech Laboratories Inc.) ) 
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7) 5’-gtttattgcagcttataatggttac-3’ (sequencing REV primer for pECFP-C1 
vector (Clontech Laboratories Inc.)) 
8) 3’- cgggactttccaaaatgtcg-5’ (sequencing FW primer for pECFP-N1 vector 
(Clontech Laboratories Inc.)) 
9) 5’- gccacaagttcagcgtgtcc-5’ (sequencing REV primer for pECFP-N1 vector 
(Clontech Laboratories Inc.)) 
2.1.5. Antibodies 
Table 1. List of primary antibodies 
Antibody Number of product Manufacturer Dilutions 
Phospho-4E-BP1 
(Thr37/46) 
Antibody 
#9459 Cell Signaling Technology 
1:500 (Western 
blot) 
4E-BP1 Antibody #9452 Cell Signaling Technology 
1:500 (Western 
blot) 
Phospho-S6 
Ribosomal 
Protein 
(Ser235/236) 
(2F9) 
#4856 Cell Signaling Technology 
1:1000 (Western 
blot) 
S6 Ribosomal 
Protein (54D2) #2317 
Cell Signaling 
Technology 
1:500 (Western 
blot) 
Rheb (E1G1R) #13879 Cell Signaling Technology 
1:500 (Western 
blot); 1:100 for IF 
Tuberin (TSC2) #4308 Cell Signaling Technology 1:200 for IF 
TOR #2983 Cell Signaling Technology 1:100 for IF 
Rabbit 
monoclonal (IgG) 
(EPR14436) to 
Arl2 
Ab183510 Abcam 
1:3000 (Western 
blot) 
1:2000 (PLA) 
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Mouse 
monoclonal 
(IgG1) (H4A3) to 
LAMP1 
Ab25630 Abcam 1:50 for IF 
PDE6D 
monoclonal 
antibody (M06), 
clone 5C7 
H00005147-M06 Novus Biologicals 1:1000 (PLA) 
Rheb monoclonal 
antibody (M01), 
clone 2C11 
H00006009-M01 Novus Biologicals 1:100 for IF 
PDE6D (N-15) Sc-50260 Santa Cruz Biotechnology 
1:300 (Western 
blot) 
mTOR antibody 
(215Q18) AHO1232 Thermo Scientific 1:100 for IF 
Arl3 10961-1-AP ProteinTech 1:100 for IF; 1:300 for WB 
Monoclonal anti-α 
tubulin T9026 Sigma Aldrich® 
1:3000 (Western 
blot) 
Table 2. List of secondary antibodies 
Antibody Number of product Manufacturer Dilutions 
IRDYE® 680RD 
Donkey anti-
rabbit 
C50821-05 LiCor® Biosciences 1:5000 
IRDYE® 800CW 
Donkey anti-
mouse 
C50924-02 LiCor® Biosciences 1:5000 
IRDYE® 800CW 
Donkey anti-goat C50917-05 
LiCor® 
Biosciences 1:5000 
Alexa 488 donkey 
anti mouse A-21202 Life Technologies 1:500 
Alexa 647 donkey 
anti rabbit A-31573 Life Technologies 1:500 
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2.1.6. Buffers and solutions 
 
10% APS   100 mg APS in 1 mL ddH20 
10x DNA sample buffer 5 mL 100% glycerol, 1 mL Bromphenolblue, 1.6 
mL 2.5% Xylene cyanole, 2 mL EDTA (0.5M, 
pH=7.4), 0.4 mL H2O  
LB agar plates add 15 g agar per liter LB medium, pour plates 
when the autoclaved medium has approximately 
55°C, add antibiotic of choice at desired 
concentration 
10x PBS (pH=7.4) 80g NaCl, 2.0g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 
(for 1L)  
1xPBS  (pH=7.4) 100 mL 10xPBS, 900 mL ddH2O (for 1L) 
1xPBS  
(0.01% Tween-20) 100 mL 10x PBS, 1 mL Tween-20, 899 mL dd H2O 
(for 1L) 
1xPBS  
(0.01% Triton-1000) 100 mL 10x PBS, 1 mL Triton-1000, 899 mL dd 
H2O  
(for 1L) 
4% PFA   4g paraformaldehyde, 100 mL 1xPBS (pH=7.4)  
(for 100mL) 
RIPA buffer  1% NaDOC, 150 mM NaCl, 1 mM Na2EDTA, 20 
mM Tris-Cl (pH=7.5), 1 mM EGTA, 2.5 mM 
Na4O7P2, 0.1% SDS, 0.1% IGEPAL, 100 μL 
Phosphatase inhibitor cocktail #2, 100 μL 
Phosphatase inhibitor cocktail #3, 1 tablet 
complete mini EDTA-free, adjust volume to 10 mL 
with ddH20 
5x sample buffer 0.6mL 1M Tris-HCl (pH=6.8), 5mL 50% glycerol,  
2 mL 10% SDS, 0.5 mL 2- glycerol, 2 mL 10% 
SDS, 0.5 mL 2-mercaptoethanol, 1 mL 1% 
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bromophenol blue, adjust volume to 10 mL with 
ddH20 
10% SDS    10g SDS in 100 mL ddH20 
10x SDS running buffer 30g Tris-Base, 144 g Glycine, 10g SDS (for 1L) 
1x SDS running buffer 100 mL 10x running buffer, 900 mL ddH2O (for 1L) 
Separating gel buffer 1.5 M Tris (pH=8.8) (18.17 g Tris-HCl in 100 mL) 
SOC medium 20 g/l Bacto-Trypton, 5 g/L bacto-yeast extract, 0.5 
g/l NaCl, 2.5 mM KCl, 10 mM MgCl2 (SOB 
medium). Autoclave and before use add 20 mM 
glucose. 
Stacking gel buffer  0.5 mM Tris (6.05 g Tris-HCL in 100 mL ddH20) 
1xTAE buffer 40mM Tris/Acetate, (pH=7.5) , 20mM NaOAc, 
1mM EDTA 
1x transfer buffer 100 mL 10x transfer buffer, 200 mL methanol,  
700 mL ddH2O (for 1L) 
10x TBS (pH=7.6)  60.6 g Tris, 87.6g NaCl (for 1L) 
1x TBST 
 (0.01% Tween-20) 100 mL 10x TBS, 1 mL Tween-20, 989 mL dd H2O 
(for 1L) 
2.1.7. Commercial solutions and kits 
 
Adenosine 5’- triphosphate, 10 mM #P0756S New England BioLabs 
BigDye® Terminator v3.1 cycle sequencing kit Applied Biosystems 
100xBSA      New England Biolabs Inc. 
Deltarasin      Chemietek 
100 mM dNTP kit     Invitrogen™ Life Technologies 
1,4-Dithiothreitol (DTT)    Gerbu Biotechnik GmbH 
2-log DNA ladder     New England Biolabs Inc.  
DUOLINK in situ detection reagents 
(far red) (DUO92013-100RXN)   Sigma Aldrich® 
DUOLINK in situ PLA probe anti-rabbit minus 
(DUO92005-100 RXN)    Sigma Aldrich® 
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DUOLINK in situ PLA probe anti-mouse plus 
(DUO92001-100 RXN)    Sigma Alrdich® 
Fermentas Tango buffer #BY5   Fermentas/Thermo Scientific 
50mM Magnesium Sulfate    Invitrogen™ Life Technologies 
Micro BCA™ Protein Assay Kit (#23235)     Thermo Scientific 
NucleoBond® Xtra Midi Plus EF   Macherey-Nagel 
NucleoSEQ Columns (1604/002)   Macherey-Nagel 
Odyssey Infrared Imaging System blocking  
buffer        LiCor® Biosciences 
10x Pfu amplification buffer   Invitrogen™ Life Technologies 
Precision Plus Protein™ standards  Bio-Rad Laboratories 
QIAquick®Gel Extraction Kit   Qiagen 
RedSafe nucleic acid staining solution #21141 iNtRON 
10x Restriction Enzyme Buffer 1   New England Biolabs Inc 
10x Restriction Enzyme Buffer 2   New England Biolabs Inc 
10x Restriction Enzyme Buffer 3   New England Biolabs Inc 
10x Restriction Enzyme Buffer 4   New England Biolabs Inc 
Rheb activation assay kit (#81201)  New East Biosciences 
Roti®-Prep Plasmid MINI (HP29.2)  Carl Roth GmbH 
Stbl3 chemically competent E. coli #C737-03 Life Technologies 
5x T4DNA ligation buffer #46300-018  Invitrogen™ Life Technologies 
10x T4 DNA ligase reaction buffer #B0202S New England BioLabs 
XL10 Gold bacterial strain    Stratagene (regrown in house) 
Zymoclean™ Gel DNA Recovery Kit (D4001) Zymo Research 
2.1.8. Cell lines and solutions for cell culture work 
2.1.8.1. Cell lines 
Table3. Cell lines used for experimental procedures 
Cell line Origin Supplier Reference 
HeLa Human cervical adenocarcinoma ATCC  
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TSC2+/+ p53-/- 
MEF 
Mouse embryonic 
fibroblast 
Kind gift of Prof. 
Dr. Aurelio 
Teleman (with 
permission of Dr. 
David 
Kwiatkowski) 
Loss of 
Tsc1/Tsc2 
activates mTOR 
and disrupts 
PI3K-Akt 
signaling through 
downregulation of 
PDGFR, JCI 
(2003) 
 
TSC2+/+ p53-/- 
MEF psp-Cas9-E 
(BB)-2A-puro 
Mouse embryonic 
fibroblast 
Made in house by 
the use of Crispr-
Cas system  
 
TSC2+/+ p53-/- 
MEF psp-Cas9-E 
(BB)-2A-puro-
sgRNA PDEδ 
Mouse embryonic 
fibroblast 
Made in house by 
the use of Crispr-
Cas system 
 
TSC2-/- p53-/- 
MEF 
Mouse embryonic 
fibroblast 
Kind gift of Prof. 
Dr. Aurelio 
Teleman (with 
permission of 
Prof. Dr. David 
Kwiatkowski) 
 
TSC2-/- p53-/- 
MEF sp-Cas9-E 
(BB)-2A-puro 
Mouse embryonic 
fibroblast 
Made in house by 
the use of Crispr-
Cas system 
 
TSC2-/- p53-/- 
MEF psp-Cas9-E 
(BB)-2A-puro-
sgRNA PDEδ 
Mouse embryonic 
fibroblast 
Made in house by 
the use of Crispr-
Cas system 
 
 
 
2.1.8.2. Solutions for cell culture work 
 
DPBS       PAN™  Biotech GmbH 
Dulbecco´s Modified Eagle´s Medium (DMEM) PAN™  Biotech GmbH 
Effectene® transfection reagent   QIAGEN 
Fetal calf serum (FCS)    PAN™  Biotech GmbH 
Fugene® 6 transfection reagent   Roche Applied Scence 
100x L-glutamine     GIBCO®/Invitrogen 
Lipofectamine™ 2000    Invitrogen™ Life Technologies 
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100x Non-essential amino acids (NEAA)  PAN™  Biotech GmbH 
Penicillin-Streptomycin    PAN™  Biotech GmbH 
Sodium pyruvate (Na-pyruvate)   PAN™  Biotech GmbH 
Trypsin/EDTA     PAN™  Biotech GmbH 
100x vitamin solution    PAN™  Biotech GmbH 
2.1.9. Materials and equipment 
2.1.9.1. Centrifuges and rotors 	
Centrifuge 5415R     Eppendorf 
Centrifuge 5417R     Eppendorf 
Centrifuge 5810R     Eppendorf 
Centrifuge RC 26 Plus    Sorvall® 
Rotor SH-3000     Sorvall® 
Rotor FA-45-24-11     Eppendorf 
Rotor FL-064-04053    Eppendorf 
Vacuum centrifuge     Eppendorf 
2.1.9.2. DNA work 	
Gel Imaging Station     Bio-Rad Laboratories 
Gene Pulser™     Bio-Rad Laboratories 
Incubator Shaker Series I26   New Brunswick Scientific 
Nanodrop® ND-1000 specrophotometer  Peqlab Biotechnologie GmbH 
Mastercycler® pro     Eppendorf 
Power Pac™ 1000     Bio-Rad Laboratories 
PMR-30 shaker     Grant-bio 
2.1.9.3. Protein work  
 
1 mm cassetes for western blot   Invitrogen™ Life Technologies 
1.5mm cassetes for western blot   Invitrogen™ Life Technologies 
1 mm 10-well combs    Invitrogen™ Life Technologies 
1.5 mm 10-well combs    Invitrogen™ Life Technologies 
Incubation box     LiCor® Biosciences 
96-well microplates (#655101)   Greiner Bio-one 
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Odyssey® CLx Imaging System   LiCor® Biosciences 
PVDF membrane     Bio-Rad Laboratories 
Sonicator needle (MS 73)    Bandelin Electronic GmbH 
Ultraschall HD 2200     Bandelin Electronic GmbH 
Test tube rotator     NeoLab 
Multiskan Ascent 96/384 plate reader  Thermo Scientific 
2.1.9.4. Cell culture work 
 
Cell scraper      Falcon/Sarstedt   
Easy Grip™ tissue culture dish    BD Falcon™ 
10 cm dish      Sarstedt 
Tissue culture plate (6-well)   Sarstedt 
E-Plate 16      ACEA Biosciences, Inc. 
4-well LabTek® chambers No.1   Nunc® 
8-well LabTek® chambers No.1   Nunc® 
Imaging Chamber CG (8-well)   Miltenyl Biotec GmbH 
Rapid Flow™ sterile disposable filter unit  
(75 mm)      Thermo Scientific 
Glass Pasteur pipettes (150mm and 230 mm) Brand GmbH & Co. KG 
CoolCell® LX freezing container   BioCision  
CryoPure Tube     Sarstedt 
NUAIRE™ Cellgard class II  
biological safety cabinet    Integra Biosciences 
Vacusafe comfort     Integra Biosciences 
Laboratory CO2 Incubator    NuAire 
Vi-Cell™ XR cell viability analyzer  Beckman Coulter, Inc. 
xCELLigence RTCA DP    ACEA Biosciences Inc. 
Heracell CO2 incubator    Thermo Fisher   
Typhoon TRIO+ variable mode imager  Amersham Biosciences 
2.1.9.5. Materials and equipment for general use  
 
Magnetic stirrer “IKMAG®RCT”   IKA® Labortechnik 
Pipettes      Eppendorf 
	 42	
Pipette tips      Eppendorf/Sarstedt   
Safe lock tubes 0.5, 1.5 and 2 mL   Eppendorf  
Falcon tubes (15 and 50 mL)   BD Falcon™ 
Heating block (QBD2)   Grant 
Parafilm®      Pechiney Plastic Packaging 
Nitrile examination gloves    Blossom® 
Latex gloves      Kimtech 
Pipetboy      INTEGRA Biosciences 
Serological pipettes (5, 10 and 25 mL)  Sarstedt 
Scale “Precisa 62 A”    Precisa Instruments AG 
Scale “Precisa 620 C”    Precisa Instruments AG 
Surgical disposable scalpel (No.11)  Braun Meslungen AG 
“Vortex Genie 1” touch mixer   Scientific Industries 
ThermoShaker (TS1)    Biometra 
2.1.9.6. Microscopes 	
Leica TCS SP5     Leica Microsystems 
AE31 trinocularAE30 Inverted Microscope Motic 
Olympus IX81     Olympus  
2.1.9.7. Software 
 
Adobe Illustrator® CS4 14.0.0.   Adobe Systems Inc. 
ImageJ 1.47k     Research Services Branch 
Lasergene 14.0.0.     DNA STAR 
Microsoft Office 2011    Microsoft  
Olympus Fluoview 4.1     Olympus Live Science 
SymPhoTime 64     PicoQuant 
Olympus Cell^R/scan^R system   Olympus Live Science 
LAS AF 2.7.3.9723     Leica Microsystems 
Image studio 5.2.     LiCor® Biosciences 
Python 2.3.7.      Python™ 
Anaconda Python Distribution   Continuum analytics 
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EndNote X7      Thompson Reuters 
Oracle VM VirtualBox 5.0.20   Oracle Corporation 
OriginPro 9.0G 32Bit    OriginLab Corporation 
Multiskan Ascent 2.6.     Ascent Software 
Vi-Cell XR 2.04     Beckman Coulter 
Quantity One® 1D Analysis Software  Bio-Rad Laboratories 
RTCA software 1.2.1    rtca-software. 
software.informer.com/1.2 
Typhoon Scanner Control v5.0   Amersham Biosciences 
 
2.2. Methods 
2.2.1. Cloning 
2.2.1.1. Transformation of chemically competent E. coli 	
The tubes with 100 μL of frozen (-80 °C) Escherichia coli XL Gold stock were 
left on ice to thaw. Once thawed, 3.25 μL of 2.25 mM DTT was added. To 
each 25 μL aliquot, approximately 50 ng (1 μL) of plasmid DNA or ligation mix 
was added, and left on ice for 30 minutes. The tubes with transformation mix 
were heat-shocked for 30-60 seconds on 42°C and returned to ice for 5 
minutes. To each tube 100 μL of SOC medium was added, and the mix was 
left on 37°C, 225 rpm for 60 minutes. 15-20 μL of the final mix was then 
added to LB agar plates containing appropriate antibiotic (kanamycin or 
ampicillin) and left overnight to grow on 37°C. 
2.2.1.2. Preparation of bacterial culture  	
After 24 h of incubation at 37°C, LB agar plates with E.coli colonies were used 
for colony picking and preparation of bacterial culture to obtain plasmid DNA. 
Few colonies from the plate were picked with a sterile pipette tip, and placed 
into their respective falcon tubes containing 5 mL (for mini-prep) or 
Erlenmeyer flask with 50 mL LB medium (for midi-prep) supplemented with 
appropriate antibiotic. The bacterial cultures were incubated overnight (16-24 
h) on 37°C, 200 rpm. 
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2.1.1.3. Preparation using Roti®-Prep Plasmid MINI kit 	
The QIAprep® Spin Miniprep Kit is used routinely to isolate up to 20 μg of 
high-purity plasmid for further use in molecular biology (PCR, cloning, 
restriction). The kit is based on alkaline analysis of bacterial cells and 
absorption of the plasmid DNA onto a silica membrane in the presence of 
high-salt buffers. DNA can be eluted from the membrane with ddH2O or low-
salt buffer. 4 mL of bacterial cell suspension (preparation described in 
2.2.1.2.) was centrifuged in 2 series (2x2mL) at 10 000rpm for 2 minutes, and 
then further steps were done as described in the manufacturer’s protocol 
(Roti®-Prep Plasmid MINI). The DNA was eluted with 30 μL of Elution buffer 
provided in the kit. 
2.2.1.4. Endotoxin-free Plasmid DNA Preparation Using NucleoBond® 
Xtra Midi EF Kit 	
Gram- negative bacteria (such as E.coli), unlike Gram-positive bacteria have 
a second membrane enclosing the inner membrane and a cell wall. The outer 
layer of this membrane consists of amphiphilic lipopolysaccharides (LPS), or 
endotoxins. They are released from cells in small amounts during cell growth, 
and in higher amounts upon cell death and lysis, hence, during plasmid 
purification. For this reason, they have to be removed during plasmid 
preparation to assure high transfection rates and viability of transfected cells.  
With NucleoBond® Xtra Midi EF Kit the endotoxin level is reduced to <0.05 
EU/μg plasmid DNA for up to 1000 μg high-copy plasmid DNA. Endotoxin-free 
plasmid DNA was prepared following NucleoBond® Xtra Midi EF Kit user 
manual. 50 mL of bacterial culture (described in 2.2.1.2.) was centrifuged for 
20 min at 4500g, 4°C. Endotoxin-free plasmid DNA was eluted by using 
NucleoBond® finalizers with 300 μL of TE- EF buffer. 
2.2.1.5. Agarose Gel Electrophoresis of DNA 	
Agarose gel electrophoresis is a method of gel electrophoresis used to 
separate DNA or proteins in an agarose matrix. An electric current to move 
the charged molecules through the agarose matrix separates biomolecules. 
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As DNA is negatively charged, it travels towards the positively charged anode. 
Polymerized agarose forms pores that depend on the concentration used, 
therefore the smallest fragments migrate faster and are closer to anode at the 
end of the when the current is stopped.  
Agarose gels were prepared with 1x TAE buffer supplemented with RedSafe 
nucleic acid staining solution (5 μL/100 mL). RedSafe emits green 
fluorescence when bound to DNA (excitation peaks: 309 nm, 419 nm, 
emission peak: 537 nm). After the gel is polymerized, it is transferred to 
electrophoretic chamber filled with 1x TAE buffer. Electrophoresis is 
preformed at constant voltage of 100 V for 30 min. DNA samples were 
prepared by mixing the DNA samples with 5x DNA loading buffer (final 
volume depends on the comb size used for the gel). DNA marker was used to 
determine the size of the DNA fragments in the gel. 
Table 4. Agarose concentration used for separation of different sized 
DNA fragments 
Agarose concentration (%) Size of DNA fragments 
2.5 <100 bp 
2 0.1 -1 kb 
1.8 0.2 – 2kb 
1.5 0.3 – 3 kb 
1.2 0.5 – 5 kb 
1 0.7 – 5 kb 
0.8 0.8 – 12 kb 
0.5 1 – 30 kb 
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2.2.1.6. Isolation of DNA fragments from agarose gels 	
The QIAquick® Gel Extraction Kit is used for gel extraction or cleanup of up to 
10 μg of DNA (70 bp to 10 kb).  It contains a silica membrane assembly for 
DNA binding in high-salt buffer and elution with low-salt buffer or water. With 
this procedure various impurities from DNA samples are removed (primers, 
enzymes, salts, agarose…) and DNA samples are eluted in the final step.  
After visualizing agarose gels for DNA fragments, the ones of interest are cut, 
put in eppendorf tube and weighed.  The appropriate amount of buffer is 
added to the slices, which are subsequently left for dissolving at 50°C for 10 
minutes. The purification is made according to the QIAquick® Gel Extraction 
Kit protocol. 
 
2.2.1.7. Restriction digestion 	
Restriction digestion or DNA fragmentation is a procedure in molecular 
biology used for DNA preparation for further processing or analysis. With the 
help of restriction endonucleases, enzymes that bind and cleave DNA 
molecules, DNA is cleaved at the restriction site. This is a specific sequence 
of nucleotides (4 to 8 base pairs in length), which are recognized by restriction 
enzymes. Restriction digestion is most commonly used for molecular cloning 
of DNA fragment into a vector. Today, most of the artificial plasmids possess 
a segment called ´multiple cloning site’ that contains various restriction sites, 
allowing insertion of almost any DNA into plasmid vectors.  
For digestion of 1μg of DNA in a 30 μL reaction mix, 3 μL of appropriate 10x 
reaction buffer (depends on the enzymes used) 1 μL of 10 U restriction 
enzyme, 3μL of 10 x BSA and ddH2O up to final volume was used. The 
reaction mix was then incubated at a temperature and time recommended by 
manufacturer (usually 37°C for 1h).  
2.2.1.8. Dephosphorylation 
Digested DNA possesses a 5´group that is necessary for proper ligation. 
However, the chance that the vector will relegate itself back, instead of 
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implementing DNA fragment of interest are very high, especially when a 
single restriction is preformed. To avoid the high fraction of empty vectors, it is 
necessary to dephosphorylate the 5´end. For this, 0.5 U/μg DNA of alkaline 
dephosphatase (calf intestinal phosphatase- CIP) is added to the reaction mix 
and the tubes were incubated for 30 minutes at 37°C.  Agarose 
electrophoresis is preformed to visualize the results, and the fragments of 
interest are cut from the gel and purified by using Zymoclean™ Gel DNA 
Recovery Kit. 
2.2.1.9. Ligation 	
Ligation is a procedure of creating recombinant DNA, by joining two DNA 
fragments from a different source together to a new DNA molecule. Ligation 
involves making a phosphodiester bond between the 3´hydroxyl of one 
nucleotide with 5´of another. This reaction requires two or more fragments of 
DNA that have blunt or compatible ´sticky’ ends, a buffer that contains ATP 
and T4 DNA ligase that connects DNA fragments with overhanging ´sticky’ or 
blunt ends. The ligation conditions require 50 ng of vector DNA and three-fold 
molar excess of insert DNA. The amount of insert is calculated according to 
the formula: 
Equation 1. 
𝑖𝑛𝑠𝑒𝑟𝑡	 𝑛𝑔 = 𝑣𝑒𝑐𝑡𝑜𝑟	 𝑛𝑔 𝑥	𝑖𝑛𝑠𝑒𝑟𝑡	𝑠𝑖𝑧𝑒		(𝑏𝑝)𝑣𝑒𝑐𝑡𝑜𝑟	𝑠𝑖𝑧𝑒	(𝑏𝑝)  
The final ligation mix contains calculated amount of insert DNA, 5x T4 DNA 
ligase buffer, 1 U T4 ligase buffer and the final volume (20 μL) was adjusted 
with ddH2O. The mix was incubated overnight at 16°C before transformation 
to chemically competent E.coli XL10 Gold.  
2.2.2.10. Polymerase chain reaction (PCR) 	
Polymerase chain reaction (PCR) is a method used for amplification of DNA, 
usually between 0.1 and 10 kbp, generating up to millions of copies of DNA of 
interest. Today it has a wide application range, starting from molecular cloning 
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and sequencing, to diagnostic, genetic identification or functional analysis. 
The major factor in the reaction is DNA polymerase, an enzyme that is 
capable of producing complementary DNA strand from the template and as 
the PCR progresses, sets in mode a chain reaction, where this template is 
exponentially amplified. A typical PCR reaction needs to contain: DNA 
template- DNA of interest that is used for amplification, DNA polymerase, 
primers- short DNA sequences that are complementary to 3´ end of each 
DNA template strand (both sense and anti-sense), deoxynucleoside 
triphosphates (dNTPs)- all four nucleotides (A, T, G, CTP) used as building 
blocks for a new DNA strand and a buffer supplemented with ions (e.g. Mg2+) 
to ensure optimal environment for the activity of the polymerase. PCR 
consists of four steps: denaturation, when double-stranded DNA helix is 
separated at a high temperature (> 90°C), annealing of primers to the 
separated DNA strand and extension of each strand through the activity of 
DNA polymerase at a lower temperature (50-70°C) and exponential 
amplification of the new DNA. The annealing temperature varies in different 
PCR reactions, as it depends on the Tm and the GC (usually 40-60%) 
percentage of the primer pair, which are specific for each DNA template. The 
final product is obtained after 25-30 cycles of the four steps, and can be 
visualized on an agarose gel.  
2.2.2.11. Making mCitrine-Rheb HVR construct 	
mCitrine-C1 vector was generated by insertion of AgeI/BsrGI PCR fragments 
of mCitrine (gift from R.Tsien) cDNA into pEGFP-C1 vector. mCitrine-Rheb 
HVR was generated by creating oligonucleotide corresponding to the last C-
terminal 20 amino acids +CAAX-box (72 nucleotides) of full-length Rheb with 
an overhang of 15 nucleotides upstream and downstream of it corresponding 
to XhoI and EcoRI cutting sites in pECFP-C1 vector (look at 2.1.4. for 
sequences of the construct and primers). The PCR reaction consisted of initial 
denaturation at 95°C for 2 minutes, 25 cycles of denaturation (95°C for 15 s), 
annealing (51°C for 30 s) and extension (68°C for 30 s). The mCitrine-C1 
vector was digested with XhoI and EcoRI, and ligated with Rheb-HVR 
amplified oligonucleotide using T4 ligase. After transformation of chemically 
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competent XL-10 bacteria with the ligation mix, positive clones were selected 
by seeding the bacterial culture on agar plate supplemented with 100 μg/mL 
Kanamycin. All constructs were verified by sequencing.  
2.2.1.12. Sequencing 	
DNA sequencing was preformed following Sanger method (Sanger and 
Coulson 1975) or dideoxy chain terminating method (Sanger, Nicklen, and 
Coulson 1977). The method is based on incorporating dideoxynucleotides 
(ddNTPs) through action of DNA polymerase during in vitro DNA replication. 
The ddNTPs lack a 3´-OH group, causing polymerase to stop the reaction 
when a certain ddNTP is incorporated, as it cannot form a phosphodiester 
bond. The method here described is based on dye-terminator sequencing, 
where each of the four ddNTPs is labeled with fluorescent dye, each of which 
emits light at a different wavelength. The nucleotides are detected by capillary 
gel electrophoresis. The in-house based Zentrale Einrichtung Biotechnologie 
provided the sequencing service. 
The typical sequencing reaction was preformed by using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit. In a 20 μL reaction, up to 300 ng DNA, 
4μL BigDye® Terminator mix, 2 μL BigDye® Terminator 10x buffer, 0.5μL 10 
mM primer of FW primer in one mix (2.1.4. section, number 6) or 8)) and the 
same volume of REV in another one (2.1.4. section, number 7) or 9)) and 
ddH20 for reaching final volume were used. The PCR reaction consisted of 
initial denaturation at 96°C for 1 min, 25 cycles of denaturation (96°C for 10 
s), annealing (50°C for 5 s) and extension (60°C for 4 min).  
Sequencing mix was cleaned up from excess of ddNTPs by using NucleoSEq 
columns according to manufacturer’s manual. Cleaned product was 
transferred to 0.5 ml Eppendorf tube, dried in a vacuum centrifuge and sent 
for analysis. 
2.2.2. Biochemistry 
2.2.2.1. Whole cell lysates preparation 	
After aspiration of medium, cells were once washed with ice-cold PBS, and 
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lysed with ice-cold RIPA buffer supplemented with 1 tablet Complete Mini 
EDTA free protease inhibitor and 100 μL of phosphatase inhibitor cocktail 2 
and 3. After 10 minutes of incubation on ice, cells were scraped and the lysate 
was transferred to a pre-cooled 1.5 mL Eppendorf tube. Samples were then 
sonicated for 12 s, cycle 3, with 30% power and centrifuged at 14 000 rpm, 
4°C for 15 minutes. Supernatant was transferred to a fresh pre-cooled 1.5 mL 
Eppendorf tube. The samples could be snap-frozen in liquid nitrogen and 
stored at -80°C until further use, or continued to be used for determination of 
protein concentration. In a last step, a proper amount of 5x loading buffer was 
added to each sample, which was then boiled for 5-10 minutes at 95°C, and 
shortly centrifuged before loading on the gel. 
2.2.2.2. Determining protein concentration 	
Total protein concentration was determined by bicinchoninic acid (BCA) 
assay. The method is based on the reduction of Cu2+ to Cu+ by protein in an 
alkaline medium, where Cu+ is colorimetrically detected using a reagent 
containing bicinchoninic acid. The final product of the reaction is purple 
colored and is formed by chelation of two molecules of BCA with one cuprous 
ion. The diluted BSA samples (range from 100-20000 ng/μL) were used as 
standards, while three reagents available from the kit (A, B and C) were mixed 
in a 25: 24: 1 dilution to make working solution. 4 μL of standards or total cell 
lysate were mixed with 80 μL of the prepared working solution and left for 
incubation at 37°C for 30 min-1h.  The samples were afterwards read in a 
spectrophotometer on 562 nM wavelength to determine their protein 
concentration.  
2.2.2.3. SDS denaturing gel electrophoresis 	
Western blot is a technique used to detect proteins in a tissue homogenate or 
extract. It is based on a gel electrophoresis to separate proteins by 3D 
structure in a native condition or denaturated proteins by size. The SDS 
denaturing gel electrophoresis was preformed with 1.5 mm gels, and each 
sample was loaded into its respective well. The samples were run at 80 V until 
the samples passed stacking gel, and 130 V while at the separating gel. 
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Following electrophoresis, electroblotting through Invitrogen system, following 
manufacturer’s manual, was preformed. The proteins were transferred to a 
polyvinyldene difluoride (PVDF) membrane, which was pre-activated with 
methanol for 5 minutes. After this, membrane, gel and two pieces of filter 
paper were left to equilibrate in a 1x transfer buffer before forming a 
´sandwich´ in a following sequence: filter paper, gel, membrane, filter paper, 
and placing it in chamber so that the proteins are traveling towards the 
positively charged cathode. In this method, transfer is preformed at 35 V, for 
1.5 h. After the finished transfer, the membrane was placed in a LiCor® 
incubation box with Odyssey Infrared Imaging System blocking buffer for 1h at 
RT. The antibodies were diluted in the fresh blocking buffer (for antibody list 
and dilutions see table 1.) and incubated on 4°C overnight. The next day, 
membranes were washed 3x5minutes with 1xTBST (0.1% Tween-20), which 
was followed by secondary antibodies incubation (diluted in blocking buffer) 
for 1h at RT. The membranes were again washed 3x5 minutes with 1x TBST 
(0.1% Tween) and the protein detection was done with Odyssey Imaging 
System. Western blots were quantified using ImageJ 1.47k (Java). The 
background of the blots was subtracted by applying the rolling ball 
substraction with a radius of 50 px. Afterwards the integrated intensity of the 
bands was measured and used for quantification. 
2.2.3. Cell culture work 
2.2.3.1. Subculturing of adherent cells 	
Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% 
non- essential amino acids (NEAA) (v/v), grown at 37 °C in a 90% humidified 
incubator with 5% CO2. DMEM without any supplements was used for 
starvation purposes.  
Cells are harvested in exponentially growth phase where approximately 70-
80% of the substrate of the culture is occupied. Cells were washed once with 
PBS to remove residues of the serum and incubated for 1 minute with 2 mL 
Trypsin/EDTA solution for detachment. Once detached, trypsin was 
deactivated and cells were resuspended in a 1:6 ratio in the new growth 
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medium and transferred to an appropriate Falcon tube. 500 μL of total cell 
suspension was used for determining final number and viability in Vi-CellTM 
XR cell viability analyzer and the desired number of cells was seeded in new 
cell culture dishes.  
2.2.3.2. Cryopreservation and storage of cells 	
Sub-confluent cells from a T75 flask were splitted as described above and 
chosen for a storage when the total number was between 800 000 and 1 500 
000 cells/mL. The cell suspension was centrifuged for 3 min on 200 rpm, and 
upon removal of the medium, the cells were resuspended in a growth medium 
containing 10% (v/v) DMSO. For cryopreservation purposes, cryoprotectants 
such as DMSO are essential to block the formation of intracellular ice crystals 
during freezing and thawing procedures. The cells in a cryo-medium were 
aliquoted in cryo-vials and transferred to CoolCell® LX freezing 
container. The boxes have control freezing rates of 1°C per minute to avoid 
cell damage. They were left on -80°C overnight and finally the cells were 
moved to -150°C freezer for long-term storage.    
Thawing procedure needs to be fast to avoid damaging ice crystals which 
form in temperatures from -120°C up to 0°C. DMSO exhibits toxic effects on 
cells on 37°C, therefore thawed cells were quickly resuspended in at least 10 
mL of growth medium and seeded in a T75 flask. After the cells attached, the 
medium was exchanged to remove any residual DMSO and the cells were 
cultured as described above. 
2.2.3.3. DNA transfection 
Transfection is a process of deliberately introducing nucleic acids in 
eukaryotic cells by non-viral methods. This method typically involves opening 
of transient pores in a cell membrane to allow the uptake of the DNA or RNA. 
Transfection methods can be chemically based, such as calcium phosphate 
precipitation, or the material can enter the cells by electroporation, cell 
squeezing or by production of liposomes, which fuse with the membrane and 
release the cargo inside the cell.  
In this study, the latter approach, lipofection, was used for transfection of DNA 
in the cells. The transfection ragents Lipofectamine ™ 2000 and Fugene ®6 
	 53	
were used, and the transfection was performed according to the 
manufacturer’s guidelines (Lipofectamine™2000: 
https://tools.thermofisher.com/content/sfs/manuals/Lipofectamine_2000_Reag
_protocol.pdf  
Fugene®6: 
https://www.promega.de/~/media/files/resources/protocols/technical%20manu
als/101/fugene%206%20transfection%20reagent%20protocol.pdf).  
Cells were plated in a 6-well or a 4 –well LabTek dish a day prior to 
transfection. For Fugene®6, the DNA: transfection reagent ratio was always 
1:3 (1μg: 3μL) and for Lipofectamine ™2000 2:1.  
 
Table 5. Transfection procedures for Fugene®6  
Vessel Surface area (cm2) 
Fugene®6 
(μL)/well 
DNA 
(μg)/well 
Serum-free 
medium 
(μL)/well 
10 cm 55 18 6 600 
6 well 9,4 3 1 100 
4 well LabTek 1,8 0,75 0,25 25 
 
Table 6. Transfection procedures for Lipofectamine™2000 
Vessel Surface area 
Lipofectamine™2000 
(μL)/well 
DNA 
(μg)/well 
Serum-free 
medium 
(μL)/well 
6 well 9,4 cm2 5-12,5 2,5 250 
4 well 
LabTek 1,8 cm
2 1-2,5 0,5 50 
 
After the transfection, the cells were cultured in a humidified incubator with 
5% CO2, on 37°C, and the medium was changed after 7-8 hours to avoid cell 
toxicity. The cells were lysed or imaged a day post-transfection.  
2.2.3.4. siRNA transfection 	
100 000 cells /well and 10 000 cells/well were seeded in full DMEM in a 6-well 
plate or 4-well Labtek dish, respectively. The following day, the cells were 
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transiently transfected with control siRNA, siRNA targeting Arl2 and Arl3 by 
using Dharmafect transfection reagent in a final concentration of 50 nM 
following manufacturer’s guidelines. After 48 hours, cells from a 6-well plate 
were lysed and effect on signaling was examined via Western blot and cells 
from a 4-well plate were used for immunofluorescence. 
2.2.3.5. Immunofluorescence 	
Day after transfection with mCitrine Rheb, the medium was aspirated from the 
wells and cells were washed once with PBS. After that, the cells were fixed for 
10 minutes at RT with Histofix and, after 3x5 minutes of rinsing with PBS, 
permeabilized for 10 minutes with PBS+0.1% Triton X-100. After another 
3x5minutes washing step with PBS, the blocking was preformed by applying 
Odyssey Blocking Buffer for 1h at RT. Primary antibodies were diluted in 
recommended ratio (see table 1.) in Odyssey Blocking Buffer and incubated 
overnight at 4°C. The next day, the antibody solution was aspirated and the 
cells were rinsed with PBS+0.1% Tween-20 3x5 minutes. Secondary 
antibodies were prepared in Odyssey Blocking Buffer (see table 2.), and 
incubated for 1h at RT. After removing the secondary antibody solution and 
final washing step with PBS+ 0.1% Tween-20 3x5 minutes, PBS was added 
to cells and the cells were stored at 4°C until imaging.  
2.2.3.6. Proximity ligation assay  
8000 cells/well were seeded in an 8-well Labtek. The next day, the cells were 
once washed with PBS and fixed with Histofix for 10 minutes, permeabilized 
with PBS+0.1% Triton X-100 for 10 minutes and blocked with a blocking 
solution (DUO92005-100RXN, Sigma-Aldrich) for 1 h at RT. Antibodies were 
diluted in experimentally determined, suitable ration (see table 1.) in Antibody 
diluent (DUO92005-100RXN), Sigma-Aldrich, and applied separately 
(negative control) and together in individual wells, and incubated overnight at 
4°C. The next day, the assay was performed according to manufacturer’s 
instructions: https://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/SigmaAldrich/Instructions/1/duolink-fluorescence-user-
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manual.pdf. The nuclei were stained with Hoechst dye diluted 1:500 in PBS 
for 15 minutes. The cells were stored at 4°C in PBS until imaging. 
2.2.3.7. Colony formation assay 	
Clonogenic assay is a cell-survival assay based on the ability of a single cell 
to grow into a colony. 100 of all cells per well were seeded in 6-well plate in 
full DMEM and incubated in a humidified incubator with 5% CO2 at 37°C for 
10 days. The medium was changed every 2 to 3 days to avoid deprivation of 
nutrients. At the day of experiment, cells were once washed with PBS, fixed 
with Histofix for 10 minutes at RT, washed 3x with PBS and incubated with 
0.01% (v/v) Crystal Violet solution. After 1 hour incubation at room 
temperature, Crystal Violet was aspirated; the wells were washed 2-3 times 
with ddH2O and left for drying. The plates were scanned with Typhoon TRIO + 
scanner (Amersham Biosciences) and analyzed using a script from (Guzman 
et al. 2014). 
2.2.3.8. Real-Time Cell Analysis (RTCA) 	
Real-time cell analysis (RTCA) is a system that enables real-time monitoring 
of cell proliferation, cellular morphology and attachment quality. An electrode-
covered surface detects electronic impedance, which increases proportionally 
with the number of cells attached.  Experiments were performed by using 16-
well E-plate on the Dual Plate xCelligence instrument (Roche Applied 
Science, Indianapolis, IN). 5000 cells of TSC2 +/+, TSC2 +/+ -/-E.V. and 
TSC2 +/+ sg RNA PDEδ MEFs and 3500 of TSC2 -/-, TSC2 -/- E.V. and 
TSC2 -/- sg RNA PDEδ MEFs were plated in each well in 200 μL of full 
DMEM. Cells were allowed to settle for 30 min at room temperature before 
being inserted into the xCELLigence instrument in a humidified incubator at 
37°C with 5% CO2. Impedance measurements were monitored every 15 min 
up to 200 hours. All assays were performed in duplicates. The growth rate 
was analyzed by calculating slope of the curve between 40 and 60 hours by 
using the following formula: 
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Equation 2. 𝑦 = 𝑦2 − 𝑦1𝑥2 − 𝑥1 
where y represents the average growth rate (slope), y2 growth rate at 60 hour 
time point, y1 growth rate at 40 hour time point, x2 is 60 hours and x1 40 hour 
time point.  
2.2.3.9. CRISPR-Cas9 system for genome engineering 	
CRISPR (Clustered regularly interspaced short palindromic repeats) are 
segments of prokaryotic DNA containing repetitions of base sequences. Each 
repetition is followed by a ‘spacer DNA’ of viral origin, result of a previous 
exposure to bacteriophages or any foreign DNA. This system represents a 
form of an acquired immunity used by bacteria and archeae, as the spacers 
are recognized and cut in a manner analogous to RNA interference in 
eukaryotic cells. This interference principle is used as a technique for genomic 
manipulation and editing of mammalian and other eukaryotic cells.  The 
CRISPR/Cas9 technique for genomic editing, based on Streptococcus 
pyogenes immune system, relies on two main components: a CRISPR-
associated 9 endonuclease (Cas 9) and a single guide RNA (sgRNA) that 
recognizes spacer region, and directs nuclease activity.  
sgRNA consists of two elements: trans-activating RNA (tracrRNA) that makes 
a complex with Cas9 and Crispr RNA (crRNA) that recognizes the region of 
interest and binds tracrRNA. Cas9 has two active cutting domains: homing 
endonuclease (HNH), that cleaves the target DNA strand and RuvC domain, 
that cleaves non-targeting DNA strand, resulting in double strand DNA break 
(DSB). Protospacer adjacent motif (PAM) sequence (5’-NGG-3’ in 
S.pyogenes) provides additional specificity for Cas9 nuclease activity as it 
immediately follows the sequence recognized by Cas9. While sgRNAs can 
transport Cas9 anywhere in the cell, the editing itself occurs only at the place 
where Cas9 recognizes PAM. DSB’s are repaired by non-homologous end 
joining (NHEJ), which can result in insertion/deletion (INDEL) mutations in a 
coding exon, leading to frame shift mutation and premature stop codons, 
silencing the gene (Figure 8. a)-c)).  
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2.2.3.9.1. Generation of stable cell lines by using Crispr-Cas9 system 		
The protocol for creating PDEδ knockout was described in (Ran et al. 2013).  
sgRNA used for knockdown are described in 2.1.4. (4) and 5)). and were 
generated by using online CRISPR Design Tool (http://tools.genome-
engeneering.org). The plasmid used for delivery was pSpCas9 (BB)-2A-Puro 
(PX4599), Addgene number: 48139 (Figure 8. d). Double stranded break in 
plasmid was repaired by use of non-homologous end joining (NHEJ). The 
ligated sgRNA-pSpCas9 (BB)-2A-Puro plasmid was treated with PlasmidSafe 
and transformed in Stbl3 chemically competent bacterial strain on an agar 
plate supplemented 100-μg/mL ampicillin. We performed mini and midi-preps 
from bacterial cultures that grew overnight at 37°C. TSC2+/+ p53-/- and 
TSC2-/-p53-/- MEFs were seeded in 1*106density in a 6-cm dish, and sgRNA-
pSpCas9 (BB)-2A-Puro plasmid or pSpCas9 (BB)-2A-Puro (empty vector) 
were transfected by using Fugene®HD transfection reagent, according to 
manufacturer’s instructions. The next day 2μg/mL of puromycin was applied 
for selection of transfected cells. The media (full DMEM supplemented with 
puromycin) was exchanged every 2-3 days until single colonies could be 
selected for subculturing and cryopreservation. 
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Figure 8. Creating cells with PDEδ knockout via Crispr-Cas system (adapted from Ran et al., 2013) 
a. The Cas9 nuclease from S. pyogenes (in yellow) is targeted to genomic DNA (shown for example is the human 
EMX1 locus) by an sgRNA consisting of a 20-nt guide sequence (blue) and a scaffold (red). The guide sequence 
pairs with the DNA target (blue bar on top strand), directly upstream of a requisite 5′-NGG adjacent motif (PAM; 
pink). Cas9 mediates a DSB (double stranded break) ∼3 bp upstream of the PAM (red triangle). b. DSBs induced by 
Cas9 (yellow) were repaired by using NHEJ (non-homologous end-joining) pathway: the ends of a DSB are 
processed by endogenous DNA repair machinery and rejoined, which can result in random indel mutations at the site 
of junction. Indel (INDEL- INsertion or DELetion of DNA bases in an organism) mutations occurring within the coding 
region of a gene can result in frame shifts and the creation of a premature stop codon, resulting in gene knockout. c. 
Steps for reagent design, construction, validation and cell line expansion are depicted. sgRNA guide sequences can 
be cloned into an expression plasmid bearing both sgRNA scaffold backbone (BB) and Cas9, pSpCas9(BB). The 
resulting plasmid is annotated as pSpCas9 (sgRNA). Completed and sequence-verified pSpCas9 (sgRNA) plasmids 
are then transfected into cells and assayed for their ability to mediate targeted cleavage. Finally, transfected cells can 
be clonally expanded to derive isogenic cell lines with defined mutations. c. Vector with sgRNA against PDEδ; U6 
promotor for guide RNA expression, sgRNA against PDEδ, CBh promotor for Cas9, 2A peptide and puromycin 
expression (the cells are selected based on their puromycin resistance). 
a. b.
c. d.
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2.2.4. Microscopy 
2.2.4.1. Laser scanning confocal microscopy 	
Images of live or fixed cells were obtained by using Olympus FluoroView 
FV1000 confocal laser-scanning microscope. DAPI/Hoechst was excited with 
405 nm, mTFP with 458 nm, mCitrine and Alexa 488 with 488 nm line of 
Argon laser. mCherry was excited with 561 nm line of DPSS laser, and Alexa 
647 with 633 nm HeNe laser. The objectives used were air objective 40x /0.9 
N.A. for PLA experiments and immersion oil objective 60x 1.2 N.A. for the rest 
of the experiments. The dichroic mirrors DM 458/515 and DM 
405/488/561/633 nm HeNe laser. The objectives used were air objective 40x 
/0.9 N.A. for PLA experiments and immersion oil objective 60x 1.2 N.A. for the 
rest of the experiments. The dichroic mirrors DM 458/515 and DM 
405/488/561/633 were used to detect the fluorescence, with 250 μM pinhole 
width. Fluorescence detection was done by acusto-optic tunable filter (AOTF) 
and SIM scanner. Bandwidth 420-460 nm was used for DAPI detection, 
through SDM 490 emission beam splitter (also separated blue from 
green/yellow fluorophores), 498-552 nm for Alexa 488 and mCitrine, through a 
SDM 560 (also separated yellow and red fluorophores), 571-650 nM for 
mCherry and BP from 655-755 nm for Alexa 647 (Figure 9.). Sequential 
imaging was performed with 3 averaged frames and by application of Kalman 
filter. Live cell imaging was performed on 37°C and fixed samples were 
imaged on room temperature. 
2.2.4.2. Fluorescence Lifetime Imaging Microscopy (FLIM) 	
Fluorescence Lifetime Imaging (FLIM) is a technique based on the differences 
between the exponential decay rates of the fluorescence from the fluorescent 
sample. Fluorescent lifetime of the fluorophore is used to produce the image, 
as it does not depend on concentration, photo bleaching, sample thickness 
etc., therefore is more robust than other intensity based methods. However, it 
depends on pH, ion or oxygen concentration or the proximity of the energy 
acceptor molecules, which makes FLIM a technique of choice for imaging in 
cells.  Usually, FLIM is applied to measure protein-protein interaction of 
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fluorescently tagged proteins by means of Förster resonance energy transfer 
(FRET). 
2.2.4.2.1. Fluorescence lifetime 	
The emission of fluorescent light consists of three stages. In the first, a single 
fluorophore molecule absorbs the energy and the electron from the ground 
state (S0) is promoted to a higher excited singlet state (S1, S2, S3…). If any of 
excited states higher than S1 are involved, the electron relaxes within a few 
picoseconds (ps) to the S1 state. This is a process of non-radiative relaxation 
or internal conversion. From S1 state, the electron relaxes back to the ground 
state by internal conversion or radiatively upon emitting a photon. This 
process occurs usually in a nanosecond (ns) range (Figure 10).  
The fluorescence lifetime (τ) is the period of time in which that electron stays 
in an excited state before emitting a photon, consequence of relaxation to 
ground state. It is defined as the inverse of the sum of the emissive (Γ) rate 
and the non-radiative decay state (knr) (Equation 3.) (Lakowicz et al. 1992; 
Bastiaens and Squire 1999; Ng et al. 1999; Wouters and Bastiaens 1999). 
Equation 3. 𝜏 = 1𝛤 + 𝑘;< 
 
2.2.4.2.2. FLIM methods 	
There are two distinct methods employed to resolve fluorescent lifetime of a 
specific compnonet in a mixture: time-domain and frequency-domain FLIM.  
Time-domain, method of choice presented in this work, relies on use of pulsed 
source to determine fluorescent lifetime. When an ultrashort pulse of light 
excites a sample, the fluorescence decays exponentially.  If the pulse or 
detection response is too wide, the fluorescence (d) is not exponential. 
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Figure 9. Instumental setting for imaging fluorescent proteins 
Excitation (dotted line) and emmission spectra (full line) of mTFP and mCitrine (A), mCitrine and mCherry (B) and 
Alexa 405 and Alexa 647 (C) with corresponding excitation laser line (black vertical line in graph) for each 
fluorophore (458 for mTFP, 515 for mCitrine (A), 488 for mCitrine, 561 for mCherry (B), 405 for Alexa 405 and 633 
for Alexa 647 (C)). Collection channel bandwidth for each fluorophore represented as a rectangle in the graph (468-
505nM  for mTFP, 525-552nM for mCitrine (A), 498-552 nM for mCitrine, 571-650 nM for mCherry (B), 420-460 nM 
for Alexa 405, 643-700 nM for Alexa 647 (C)). Spectra obtained from: http://epys.df.uba.ar/ 
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Figure 10. Jablonski diagram (made by: K.C. Schürmann) 
 explains how electrons in common fluorophores are excited from the ground state into higher energy states, and 
how these excited molecules relax by photon emission and other mechanisms to fall back into the ground-level 
energy state. S0-ground state; S1-S2- excited states. 
 
 
Therefore, the instrument response function (IRF) is convolved with the decay 
function (F) (Equation 4.). IRF is usually measured by use of scattered 
excitation light or measuring a sample with an extremely short lifetime (rose-
bengal solution). 
 
Equation 4. 
    𝑑 = 𝐼𝑅𝐹 ∗ 𝐹 
 
The correct contribution of each fluorophore in a mixture can be determined 
by fitting the decay to biexponential function if both fluorophores have a 
monoexponential lifetime (Lakowicz 1988).  
Frequency-domain FLIM uses a phase-modulation method to determine 
fluorescence lifetime. Light source is pulsed or modulated at high frequency 
(i.e. continuous wave source combined with a modulator) and the 
fluorescence is demodulated and phase shifted, which is related to decay of 
the fluorophore (Lakowicz 1988; French, Gratton, and Maier 1992).  
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2.2.4.2.3. Time-Correlated Single-Photon Counting (TCSPC) 	
Since variations in source intensity and photoelectron amplitudes are ignored, 
the time correlated single photon counting (TCSPC) is applied to measure 
fluorescence lifetimes in time-domain FLIM.  
TCSPC records times at which individual photons are detected by a photo-
multiplier tube (PMT) or an avalanche photo diode (APD) after a single pulse. 
The recordings are repeated for additional pulses and after enough recorded 
events; one is able to build a histogram of the number of events across all of 
the recorded time points (Lakowicz et al. 1992; O'Connor 1984). The 
histogram can be fitted to an exponential function that contains the 
exponential lifetime decay function of interest, and the lifetime parameter can 
accordingly be determined (Figure 11.). To obtain information of localization 
of the protein or the dye in the cell, TCSPC is combined with a scanning 
microscope.  
 
 
 
 
 
 
 
 
 
 
Figure 11. Principles of time-correlated single-photon counting (TCSPC) (adapted from: (Becker 2015) 
 
TCSPC repetitively and precisely registers single photons in a sample. Pulsed laser source repetitively excites the 
sample, and emitted photons are detected with a photomultiplier, which acts as a stopwatch, as it measures arrival 
time of a photon in respect to the excitation pulse. By counting many events, histogram of arrival times of excited 
photons is built up. This histogram can be fitted to an exponential function, from which a lifetime of a sample can be 
determined.  
 
2.2.4.2.4. Förster resonance energy transfer (FRET) 	
FRET is a mechanism describing energy transfer between two light-sensitive 
molecules (fluorophores). Donor fluorophore, in the excited state, transfers 
energy to an acceptor fluorophore through non-radiative dipole-dipole 
coupling, thereby relaxing back to the ground state. The efficiency of this 
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process is inversely proportional to the sixth power of the distance between 
donor and acceptor (typically 1-10nm), making FRET extremely sensitive to 
small changes in distance (Equation 5.). 
Equation 5. 𝐸C = 	 𝑅DE𝑅E +	𝑅FE  
 
ET= energy transfer 
R= donor-acceptor distance  
Ro= donor acceptor distance when FRET efficiency is 50% (Förster radius) 
 
Equation 6. 𝑅D = 2,8 ∗ 10JK ∗ 𝜅M ∗ 𝛷O ∗ 𝜂QR ∗ 𝐽(𝜆) 16 
 
The Förster radius depends on the orientation factor of the transition dipoles 
of the fluorophores (κ), the donor quantum yield (ΦD) (Equation 7.), the 
refractive index of the medium (η), and the integral of the overlap- ping 
spectra (J(λ)) (Equation 6.).  
Equation 7. 
𝛷 =	 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑒𝑚𝑖𝑡𝑡𝑒𝑑	𝑝ℎ𝑜𝑡𝑜𝑛𝑠𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑	𝑝ℎ𝑜𝑡𝑜𝑛𝑠 
 
The refractive index, the overlap integral, and the orientation of the dipoles 
should be constant for each specific FRET pair. Therefore, the FRET 
efficiency is only governed by the change in distance, and it can occur only 
between two interacting proteins (Förster 1948; Clegg 1992). 
2.2.4.2.5. Global analysis 	
In samples with multiple lifetime components, it is very difficult to determine 
the contribution of each species in the mixture. A biexponential fitting in each 
pixel requires a large amount of collected photons in each pixel, which is 
unfeasible due to long acquisition times and excessive photobleaching. An 
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alternative method is global analysis of data sets, which assumes the lifetimes 
to be spatially invariant. This allows decoupling the determination of the 
lifetimes (global) from the relative contributions of the species in each pixel 
(local). It relies on a Fourier transform of the fluorescence decay curve that is 
calculated for each pixel and representation of the complex Fourier 
components on a phasor plot where the x-axis is the real, and the y-axis the 
imaginary component. The global lifetimes are calculated from the distribution 
of phasors. In FRET-FLIM only the lifetime of the donor is measured. If the 
donor molecule interacts with the acceptor molecule, the energy transfer 
occurs and the donor fluorescence decays faster, shifting its lifetime to lower 
values. If these two lifetimes are constant across the sample, global analysis 
is applicable and the relative contributions of each species, the interacting 
fraction of the proteins (α) (Equation 8.), can be calculated for each pixel. 
(Grecco, Roda-Navarro, and Verveer 2009).   
Equation 8. 
𝛼 = 𝐷𝐴𝐷 + 𝐷𝐴  
Additionally, the donor only average lifetime (τD) and FRET lifetime (τF) can be 
used to calculate the FRET efficiency (Equation 9.) 
Equation 9. 
 𝐸 = 1 − ]^]_ 
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Figure 12. Global analysis and phasor plot (adapted from Grecco et al., 2010) 
 
2D plot where the x-axis is the real component and the y-axis the imaginary component of the complex Fourier 
coefficients; values on the semicircle correspond to monoexponential lifetimes. The fluorescent decay of each pixel is 
transformed into a unique position on a phasor plot. The resulting distribution is used to fit a straight line, whose 
intersects with the semi-circle constitute the values of τD (donor lifetime) and τF (FRET lifetime). The values for 
interacting fraction of the proteins (α) in each pixel of the sample are calculated from the projection of the respective 
phasors onto the line.  
 
2.2.4.2.6. Acquisition and analysis of the FRET-FLIM data 
FLIM measurments were made in a setup composed of Olympus FluoroView 
FV1000 laser scanning confocal microscope equipped with time-correlated 
single-photon counting module (TCSPC) (LSM Upgrade Kit, Picoquant). 
Photons were detected by using a single-photon counting avalanche 
photodiode (PDM Series, MPD) and the signal was transferred to digitally 
modulated driver (PicoHarp 300). For mCitrine detection, the sample was 
excited using a 510 nm diode laser (64%) (LDH510, Picoquant) at a 40 MHz 
frequency by APD equipped with bandpass filter 530/11 nm. The fluorescence 
was collected through an oil immersion microscope (60x/1.35 UPlanSAPO, 
Olympus) and filtered by using the dichroic mirror DM 405-442/510. For 
mTFP, 470nM pulsed laser (36%) and filter 480/20 nm was used, and the 
dichroic mirror used for detection of the fluorescence was 458/515 nm (Figure 
13).   
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The lasers were controlled with the SymPhoTime software (PicoQuant GmbH) 
with pulse repetition every 25 ns. The resulting .pt3 or .ptu files were 
subjected to MatLab (Mathworks) based autoglobal analysis (see global 
analysis). Donor count (DC) image was used to create masks for raw lifetime 
(lt) and alpha (α) images in ImageJ 1.47k (Java). 
2.2.5. Analysis 
2.2.5.1. PLA distribution analysis 
Angel Stanoev performed analysis for PLA according to the instructions: for 
the estimation of PLA punctae localization relative to the nucleus, we 
calculated the distance between each punctum and the nuclear center. Cell 
shape affects this distribution; therefore, every measured cell was compared 
to a random distribution of PLA punctae to nuclear center, as a reference. 
This random distribution was generated by measuring the distances of each 
cell pixel to the nuclear center for each individual cell mask. Averaging these 
distributions across all the cells produced the average random distribution of 
PLA punctae distances to the nuclear center. This approach is equivalent to 
calculating the randomized distributions in a Monte Carlo fashion. 
2.2.5.2. Analysis of protein intensity distribution 	
             The experiments were done in Anaconda Python (2.7) software by using 
segmentor tool. For each pixel in the cell, the distance to nucleus and plasma 
membrane was determined. The cells were divided to 3 spatial bins 
(1=closest to the plasma membrane, 3= closest to the nuclear membrane), 
with equal radius between them (segment thickness identical across the cell). 
For angular masking, the center of the nucleus was determined and the 
intensity weighted ‘center of the cell’ and a central axis was fitted to these two 
points. 60° around the axis was used for the analysis of intensity distribution, 
and in the WT image section the image used for the weighting was typed in. 
Images for segmentation were defined to appear in a designated order, with a 
corresponding intensity profile. Each value of the segment was normalized to 
the sum of intensity in all segments, and the resulting mean value with the 
standard deviation was plotted in the graph. P values were determined by a 
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Student’s unpaired t-test. All values <0.05 were determined as not significant.  
 
Figure 13. Instrumental setting for FLIM 
Spectra of used FRET pairs (mTFP as donor and mCitrine as an acceptor in A, mCitrine as donor and mCherry as 
an acceptor in B). Pulsed lasers used for excitation of donors are represented as vertical lines in the graph (440 nM 
for mTFP (A) and 510 nM for mCitrine (B)). Detection bandwidth for donor mTFP is from 470-490 nM (A) and 
mCitrine from 524-535 nM (B), represented as rectangle in the graph. Spectra from: http://epys.df.uba.ar/ 
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3.RESULTS 
3.1. Rheb is localized in the perinuclear region of the cell due 
to PDEδ-Arl2 interaction 
3.1.1. Rheb and mTOR are localized in the perinucelar area of the cell 	
In order to determine the localization of Rheb in the cell, we ectopically 
expressed mCitrine-Rheb and performed immunofluorescence (IF) on 
endogenous Rheb in mouse embryonic fibroblasts immortalized through p53 
knockout (TSC2+/+ p53-/- MEFs, in the remaining text TSC2+/+ MEFs). Both 
endogenous and fluorescently tagged protein displayed a significant 
enrichment in the perinuclear area of the cell, with the majority of this intensity 
co-localizing with the lysosomal marker, Lamp1 (Figure 14. a.). This is the 
reported organelle where the interaction of Rheb with its effector, mTOR 
occurs (Sancak et al. 2008).  
In order to examine whether mTOR and Rheb are found in the same area of 
the cell, we performed IF on endogenous Rheb and mTOR in TSC2+/+ MEFs. 
To quantify the spatial distribution of proteins, cells were divided in 3 
segments with equal radius (1- closest to the plasma membrane, 3-closest to 
the nuclear membrane), and the 60° angle around the longitudinal cellular 
axis was used to determine the distribution of mCitrine-Rheb (‘segmenting 
analysis’ in the remaining text) in each cell line. Both proteins displayed high 
co-localizing perinuclear concentration (Figure 14. b.), which indicated that 
the wider perinuclear area of the cell is the region where the interaction 
between Rheb and mTOR occurs. 
In order to investigate whether Rheb localization is influenced by interaction 
with mTOR, we ectopically expressed mCitrine-Rheb in serum-starved 
TSC2+/+ MEFs and monitored its perinuclear enrichment after stimulation 
with insulin. We observed an increase in perinuclear intensity of mCitrine-
Rheb, suggesting that active Rheb is recruited in the perinucelar area through 
interaction with effector mTOR (Figure 14. c.).  
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Figure 14. Rheb and mTOR localize at the perinuclear area of the cell 
a. Representative (immuno) fluorescence micrographs of endogenous Rheb (upper image), mCitrine-Rheb (lower 
image) (first column) and Lamp1 (second column) in TSC2+/+ MEFs. Overlay of Rheb and mCitrine-Rheb with 
Lamp1 (third column). Graph: Ratio of mean Rheb or mCitrine Rheb intensity co-localizing with Lamp1 versus total 
cell intensity ± s.d. n>20 for both. b. Representative immunofluorescence micrograph of mTOR (green) and Rheb 
(magenta), with their overlay (third image) in TSC2+/+ MEFs. ). Graphs: quantification of mCitrine-Rheb intensity in 
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three separate cell segments  (1-closest to plasma membrane (PM), 3-closest to nuclear membrane (NM)) using a 
60° angle around an intensity weighted cellular axis. n> 20. c. Serum-starved TSC2+/+ MEFs expressing mCitrine-
Rheb. Stimulation with 300 nM insulin after 1 min of imaging. Red arrow indicates perinuclear area used for 
quantification. Graph: quantification of perinuclear mCitrine-Rheb fluorescence intensity, normalized to pre-insulin 
addition value (y-axis), time in minutes (x-axis). Red thick curve: average of all mCitrine-Rheb curves. n=4. Scale 
bars= 10μm. 
 
3.1.2. PDEδ interacts with Rheb and is essential for its perinuclear 
enrichment  	
Endogenous Rheb displayed higher intensity level in the nucleus, compared 
to mCitrine-Rheb. This indicated that a substantial soluble fraction of Rheb 
exists at the endogenous level. When mCitrine-Rheb was co-expressed with 
red fluorescent protein tagged PDEδ (mCherry-PDEδ), its nuclear, soluble 
fraction was increased proportionally to the expression of the solubilizer, 
mCherry-PDEδ. This indicated that PDEδ acts as a solubilizing factor for 
Rheb (Figure 15. a.). 
To observe the interaction between PDEδ and Rheb in live cells, we 
performed fluorescence lifetime imaging microscopy of Förster resonance 
energy transfer (FLIM-FRET) in transiently co-transfected MEFs with 
mCitrine-Rheb and mCherry-PDEδ (Figure 15.b.). The homogenous 
fluorescence patterns of both mCitrine-Rheb and mCherry-PDEδ indicated 
that Rheb is indeed solubilized by PDEδ, which was confirmed by the 
decrease in donor (mCitrine) lifetime (τav) from approximately 3 ns to 2.85 ns 
(upper graph) and computed molar fraction of interacting proteins (α), which 
increased proportionally to expression of the acceptor (lower graph). After 
addition of 3 µM of the small-molecule PDEδ inhibitor, Deltarasin 
(Zimmermann et al. 2013) the loss of mCitrine-Rheb soluble state was 
immediate and this was reflected in increase of donor lifetime comparable to 
donor-only control and decrease of α (see graphs). 
Since the treatment with Deltarasin resulted in loss of PDEδ-Rheb interaction, 
we used it to determine whether the perinuclear Rheb localization is 
generated by action of PDEδ. For this, we transiently co-expressed the 
mCitrine-tagged hypervariable region of Rheb (mCitrine-Rheb HVR) and full-
length mCherry-Rheb and monitored perinuclear localization of both after 
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addition of 3 µM of Deltarasin (Figure 15.c.). We observed a gradual 
decrease of perinuclear enrichment for both proteins over the course of 
approximately 15 minutes. This showed that perinuclear localization of Rheb 
is maintained through the interaction of its farnesyl group in the HVR with 
PDEδ. 
Quantitative Western blot analysis, examining phosphorylation of mTORC1 
downstream effectors S6P and 4EBP1 was performed to examine the role of 
this perinuclear Rheb localization on the activity of its main effector, mTORC1. 
Treatment with increasing concentration of Deltarasin decreased the 
phosphorylation of mTORC1 effector, ribosomal protein S6 (S6P) and 
eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) (Figure 
16.), indicating that the perinuclear concentration of Rheb, maintained by 
PDEδ-mediated solubilization, is necessary to maintain proper mTORC1 
signaling in cells.   
3.2. TSC2 GAP activity is coupled to the PDEδ/Arl2 mediated 
spatial cycle of Rheb 	
3.2.1. TSC2 co-localizes with Rheb 
 
The only known regulatory protein, determining the guanine nucleotide 
loading of Rheb is its GAP, TSC2. It is active and promotes hydrolysis on 
Rheb in cells deprived of growth factors and nutrients. . In serum-starved 
TSC2+/+ p53-/- MEFs, TSC2 displayed higher perinuclear localization 
compared to the cells grown in full medium (Figure 17.a.). Interestingly, TSC2 
localization is not completely perinuclear in serum starved conditions, which 
confirms the previous reports that in order to completely recruit TSC2 to the 
lysosomal surface, the lack of both growth factors and amino acids must be 
present (Demetriades, Doumpas, and Teleman 2014). Additionally, Rheb 
and TSC2 displayed high co-localization in the perinuclear area of the cell, as 
analyzed by segmenting analysis (Figure 17.b.). This indicated that the 
perinuclear region of the cell is as well the area of activity regulation of Rheb, 
as it is the area of Arl2-GTP mediated release of Rheb from PDEδ, resulting 
in Rheb enrichment on membranes in this area of the cell.  
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Figure 15. PDEδ is necessary for perinuclear enrichment of Rheb and mTOR signaling 
a. Representative fluorescence micrographs of endogenous Rheb (left), mCitrine Rheb (middle) and mCherry PDEδ 
(right) in TSC2+/+ MEFs. Graphs: Ratio of mean nuclear Rheb, mCitrine Rheb and mCitrine Rheb co-expressed with 
mCherry PDEδ intensity versus total cell intensity ± s.d. (left). Nuclear versus total cell mCitrine Rheb intensity in 
single cells (x-axis) as a function of mCherry PDEδ expression (y-axis). Red line represents linear fit for the entire 
dataset. n>20 for both. 
b.  FRET-FLIM measurements of the interaction of mCitrine-Rheb and mCherry-PDEδ before (-) and after addition of 
Deltarasin (+3 μM Deltarasin). For each sample, the fluorescence intensity of the indicated proteins (upper two rows), 
the spatial distribution of the mean fluorescence lifetime (τav) in nanoseconds (third row) and the molar fraction of 
interacting molecules (α) (fourth row) are shown according to the false-color look-up tables. Left graph: quantification 
of average lifetimes of donor only (D), donor-acceptor complex (DA) and donor acceptor complex after Deltarasin 
addition (DA+DR) ± s.d. Right graph: quantification of interacting fraction α before and after Deltarasin addition as a 
function of mCherry-PDEδ expression. Black arrows indicate decrease in α after Deltarasin addition for all cells. n=8. 
c. Time series of mCitrine-Rheb-HVR (upper row) and mCherry-Rheb (lower row) relocalization after application of 
3μM Deltarasin. Perinuclear fluorescence intensity was used for quantification (red arrow). Graph: quantification of 
perinuclear mCitrine-Rheb HVR (black) and mCherry-Rheb (red) fluorescence intensity, normalized to pre-Deltarasin 
addition value (y-axis), time in seconds (x-axis). Black thick curve: average of all mCitrine-Rheb HVR curves, red 
thick curve: average of all mCherry-Rheb curves. n=4. All p-values were obtained by unpaired t-test. All scale 
bars=10 μM.  	
 
 
Figure 16. PDEδ inhibition impairs mTORC1 signaling 
 
Western blot analysis of TSC2+/+ MEFs. Phosphorylation levels determined before and after 15-minute stimulation 
with 300 nM insulin. Left panels: representative western blots of (top to bottom) p4EBP1, 4EBP1, pS6P, S6P and 
loading control, and tubulin. Graphs: quantification of p4EBP1/4EBP1 (left) and pS6P/S6P (right) normalized to 
insulin-stimulated control. 
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Figure 17. TSC2 is perinuclear and co-localizes with Rheb 
a. Representative immunofluorescence micrographs of TSC2 with (left) and without (right) serum.  Graph represents 
quantification of TSC2 intensity in three separate cell segments (PM-plasma membrane, NM- nuclear membrane).  b.  
Immunofluorescence micrographs of Rheb (green) and TSC2 (magenta) and their overlay (third image) IN TSC2+/+ 
cells. Graph: quantification of protein intensity in three cellular segments.  		
3.2.1. Solubilization by PDEδ is necessary to maintain Rheb localization 
and mTORC1 signaling in growth factor responsive cells 
 
In order to investigate the contribution of PDEδ-mediated solubilization of 
Rheb and its own activity state, mediated by the GAP TSC2, on Rheb 
localization and mTOR signaling, we generated TSC2+/+ and TSC2-/- MEFs 
with PDEδ knockout via Crispr-Cas system (Jinek et al. 2012; Ran et al. 
2013). TSC2-/- MEFs have a knockout of Rheb GAP, TSC2, which results in 
constitutively active Rheb-GTP and constant activation of mTORC1 (Zhang et 
al. 2003). The intensity distribution of mCitrine-Rheb was quantified by 
dividing the cells into three segments with equal radius (1-closest to the 
plasma membrane, 3-closest to the nuclear membrane), and the values within 
60° angle around the longitudinal intensity weighted cellular axis taken into 
account. The distribution of mCitrine-Rheb in TSC2+/+ E.V. (empty vector) 
control cells increased towards the 3rd cellular segment, while in TSC2+/+ 
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MEFs with PDEδ knockout (sgRNA PDEδ) the intensity profile was 
significantly flatter (Figure 18.a.). We also performed Western blot analysis 
on S6P phosphorylation in TSC2+/+ E.V. and sgRNA PDEδ MEFs before and 
after 15-minute stimulation with insulin, to determine the effect of perinuclear 
Rheb concentration, mediated by PDEδ solubilization, on mTOR activation. 
S6P phosphorylation was significantly reduced as compared to the control in 
unstimulated TSC2+/+ sgRNA PDEδ MEFs. These cells maintained 
responsiveness to insulin, as apparent from the increased S6P 
phosphorylation, albeit to a significantly lower extent than the control TSC2+/+ 
E.V. cells (Figure 18.b.). 
 
3.2.3. Rheb solubilization depends on its nucleotide-bound state 
 
In contrast to previous results, TSC2-/- MEFs displayed no mislocalization of 
mCitrine-Rheb nor inhibitory effect on mTORC1 signaling, as determined by 
S6P phosphorylation levels, regardless of the presence of PDEδ (Figure 18. 
c.-d.).  
Interestingly, the distribution of mCitrine-Rheb HVR in both TSC2 +/+ and 
TSC2 -/- sgRNA PDEδ MEFs decreased significantly in the 3rd cellular 
segment compared to their respective E. V. controls (Figure 19. a., b.). This 
indicates that the perinuclear concentration of Rheb depends not only on the 
PDEδ- mediated solubilization, but as well its own activity state. 
This was additionally confirmed by expressing mCitrine-Rheb in parental 
TSC2+/+ and TSC2-/- MEFs, where its measured perinuclear fraction was 
significantly higher in TSC2-/- MEFs, compared to TSC2+/+ MEF (Figure 
20.a.).  
The co-expression of mCherry-PDEδ resulted in reduced mCitrine-Rheb 
perinuclear fraction in both cell lines, albeit to a lower extent in TSC2-/- MEFs. 
Single cell analysis uncovered that the gradual decrease of perinuclear 
mCitrine-Rheb fraction occurs with increasing expression of mCherry-PDEδ,  
while only at the very high levels of mCherry-PDEδ, a minor loss of 
perinuclear mCitrine-Rheb in TSC2-/- MEFs was observed (Figure 20. b.)  
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Figure 18. Solubilization by PDEδ is necessary to maintain Rheb localization and mTORC1 signaling in 
growth-factor responsive cells 
(a.,c.) Fluorescence intensity patterns of mCitrine-Rheb in TSC2+/+ (a.) and TSC2-/- MEFs (c.) stably expressing 
empty vector (E.V., upper images) and guide RNA for silencing PDEδ (sgRNA PDEδ, lower images). Graphs: 
quantification of mCitrine-Rheb intensity in three separate cell segments  (1-closest to plasma membrane (PM), 3-
closest to nuclear membrane (NM)) using a 60° angle around an intensity weighted cellular axis. n> 20 for each 
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condition. Scale bars= 10μm. (b.,d.) Western blot analysis of S6P phosphorylation in TSC2+/+ E.V. MEF and 
TSC2+/+ sgRNA PDEδ MEF (b.) and TSC2-/- E.V. MEF and TSC2-/- sgRNA PDEδ MEF (d.). Phosphorylation levels 
were determined prior and post-stimulation with 300 nM insulin for 15 minutes. Left panels: representative western 
blots of five independent experiments for each cell line. From top to bottom row: phosphorylation of S6P (pS6P), total 
levels of S6P (S6P), PDEδ and loading control (tubulin). Graphs: quantification of pS6P/S6P normalized to insulin-
stimulated control cell line (E.V. + insulin). 
 
In order to investigate whether this perinuclear Rheb concentration is 
necessary for mTORC1 activation, we analyzed the level of S6P 
phosphorylation in cells as a function of ectopic mCherry-PDEδ expression 
via Western blot analysis. Compatible with the results described above, we 
observed decrease in S6P phosphorylation with increased level of mCherry-
PDEδ expression, while it remained unchanged in TSC2-/- MEFs (Figure 
20.c.). 
Altogether, these results show that solubilization by PDEδ is an essential step 
in generating high enough perinuclear concentration of Rheb to engage and 
activate mTOR. The solubilization is superseded in TSC2-/- MEFs, due to 
stable interaction of constitutively active Rheb-GTP with mTOR, resulting in 
increased perinuclear fraction of Rheb-GTP, impaired solubilization and 
unhampered mTORC1 signaling.  
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Figure 19.  
(a., b.) Fluorescence intensity patterns of mCitrine-Rheb HVR in TSC2+/+ (a.) and TSC2-/- MEFs (b.) stably 
expressing empty vector (E.V., upper images) and guide RNA for silencing PDEδ (sgRNA PDEδ, lower images). 
Graphs: quantification of mCitrine-Rheb HVR intensity in three separate cell segments  (1-closest to plasma 
membrane (PM), 3-closest to nuclear membrane (NM)) using a 60° angle around an intensity weighted cellular axis. 
n> 20 for each condition.  
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Figure 20. mTOR signaling and perinuclear enrichment of Rheb depends on nucleotide bound state of Rheb  
 
a. Images of TSC2+/+ (left) and TSC2-/- MEFs (right) ectopically expressing mCitrine-Rheb. Graph: quantification of 
perinuclear mCitrine-Rheb integrated intensity vs. total cell intensity in both cell lines.  
b. Representative fluorescence micrographs of mCitrine Rheb fluorescence intensity in TSC2+/+ MEFs (left, n=28) 
and TSC2-/- MEFs(right, n=34) with co-expression of mCherry-PDEδ (lower images). Graphs, left: Perinuclear 
mCitrine-Rheb intensity (y-axis) in dependence on mCherry-PDEδ expression level (x-axis) in both cell lines. Values 
on both axes are normalized to total mCitrine-Rheb intensity. Lines represent linear fit for each individual dataset 
(black=TSC2+/+; red= TSC2-/-). Statistical difference between two datasets determined by F-test with resulting p 
value of 0.2.  
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c. Representative expressing mCherry PDEδ. p value obtained by unpaired t-test. All scale bars= 10 μM.  c. Left: 
Linear fit of western blot data on S6P phosphorylation as a function of ectopic mCherry-PDEδ expression level in 
TSC2+/+ MEFs (black) with a or TSC2-/- MEFs (red). n=3. p value obtained by unpaired t-test. 
 
3.2.4. Arl2-mediated localized release generates perinuclear membrane-
associated Rheb  	
Although it was reported that both Arl2 and Arl3 displace farnesylated Ras 
proteins from PDEδ, knockdown of Arl2 only, not Arl3 (Figure 21. e.) lead to 
increased solubilization of Rheb in TSC2+/+ MEFs (Figure 21. a.), effect 
observed in other Ras proteins as well (Schmick et al. 2014). Accordingly, 
knockdown of Arl2 lead to a decreased phosphorylation rate of S6 in these 
cells (Figure 21. c.). On the other hand, localization of mCitrine-Rheb in 
TSC2-/- MEFs with a Arl2 or Arl3 knockdown did not lead to any visible 
change (Figure 21. b.), and phosphorylation of S6 remained the same, 
regardless of the presence of Arl2 (Figure 21. d.). These results show that 
impairing the PDEδ/Arl2-GTP mediated spatial cycle of Rheb by removing 
either of the two factors results in mislocalization of Rheb in growth factor 
responsive cells only, while it has no effect in cells with constitutively active 
Rheb. This implies that the Rheb spatial cycle mediated by PDEδ/Arl2-GTP is  
coupled to the Rheb nucleotide bound state, as well that it is necessary for the 
perinuclear accumulation in growth factor-responsive cells. 
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Figure 21. Arl2-mediated perinuclar enrichment of Rheb is necessary for mTORC1 signaling  
(a,b) Representative maximal intensity projections of z-stacks of mCitrine-Rheb distribution in TSC2+/+ (a.) and 
TSC2-/- MEFs (b.) cells transfected with non-targeting siRNA (cRNA), siRNA against Arl2, Arl3 or both. Graphs: 
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mean nuclear/total cell intensity ± s.d. n> 16 for each condition. Scale bars=10μm. (c,d) Western blot analysis of S6P 
phosphorylation in TSC2+/+ (c) and TSC2-/- MEFs (d) with siRNA-mediated knockdown of Arl2 or Arl3 or both. 
Phosphorylation levels were determined 48h post siRNA transfection. Left panels: representative western blots of 
three independent experiments for each cell line. From top to bottom row: phosphorylation of S6P (pS6P), total levels 
of S6P (S6P), Arl2, Arl3 and loading control (tubulin). Graphs: quantification of pS6P/S6P normalized to control RNA 
transfected cells. e. Quantification of expression level of Arl2 or Arl3 from c,d. Data in c,d,e is shown as mean ± 
s.e.m. All p values were obtained by unpaired t-test. P values >0.05 labeled as not significant (n.s.). 
 
3.3.  Allosteric displacement of Rheb from PDEδ via Arl2-GTP 
activity occurs in the perinuclear area of the cell 
3.3.1. Interacting proteins Arl2 and PDEδ 
 
Arl2-GTP activity has been shown to displace farnesylated Ras proteins from 
PDEδ. It was shown that this activity needs to be restricted to a confined area 
of the cell, and the results above indicated that this is the perinuclear region.  
In order to confirm the interaction between Arl2 and PDEδ we performed 
fluorescence lifetime imaging microscopy of Förster resonance energy 
transfer (FLIM-FRET) to determine the whether the interaction between PDEδ 
and Arl2 occurs in this area of the cell. 
Ectopically expressed teal fluorescent protein-tagged Arl2 (mTFP-Arl2) and 
PDEδ fused to red fluorescent protein (mCherry-PDEδ) showed a 
homogenous distribution of interacting molecules (Figure 22. a.). However, 
immunofluorescence (IF) of endogenous Arl2 and PDEδ demonstrated that 
Arl2 is significantly enriched in the perinuclear region, compared to flatter 
PDEδ (Figure 22. b.), what was not observed in distribution of fluorescently 
tagged-Arl2. This indicated that the interaction of these proteins should take 
place mostly in this part of the cell. According to previously published data 
(Schmick et al. 2014), and the data presented here, the displacement of 
farnesylated cargo, therefore, the interaction between Arl2-GTP and PDEδ 
occurs in the locally, at the area of the cell.  
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Figure 22. Interaction and localization of Arl2 and PDEδ  
a. FRET-FLIM measurements of the interaction of mTFP-Arl2 and mCherry-PDEδ). For each sample, the 
fluorescence intensity of the indicated proteins (upper two rows), the spatial distribution of the mean fluorescence 
lifetime (τav) in nanoseconds (third row) and the molar fraction of interacting molecules (α) (fourth row) are shown 
according to the false-color look-up tables. Upper graph: quantification of average lifetimes of donor only (D) and 
donor-acceptor complex (DA) ± s.d. Lower graph: quantification of interacting fraction α. n=12. 
b. Representative immunofluorescence micrographs of PDEδ (upper) and Arl2 (lower) in TSC2+/+ MEFs with DAPI 
stain for nucleus. Graph represents quantification of PDEδ (black line, n=55) and Arl2 (red line, n=43) fluorescence 
intensity distribution in three cellular segments (1- closest to the plasma membrane (PM), 3- closest to the nuclear 
membrane (NM)) ± s.d. P values were determined by unpaired t-test. 
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3.3.2. Arl2 and PDEδ interact in the perinuclear area of the cell 
 
In order to determine the interaction between two proteins at the endogenous 
level we preformed in situ proximity ligation assay (PLA) (Soderberg et al. 
2006) (Figure 23.). PLA results in fluorescent puncta in the areas where 
interaction between two proteins ocurrs (Koos et al. 2014). The release of the 
farnesylated cargo should be independent on its own nucleotide bound state, 
but dependent on GTP-loaded state of Arl2. Therefore, we examined 
interaction pattern of Arl2 and PDEδ in TSC2+/+, TSC2-/- and HeLa cells.  To 
determine the distribution of Arl2-PDEδ interaction puncta in the cell, we 
computed the position of the nuclear membrane in the cell and the distance of 
each punctum to the center of the nucleus. The resulting distribution was 
compared to a calculated randomized puncta distribution, calculated by 
determining the distance of each cell pixel to the nuclear center (Figure 23., 
Figure 24.). The distance distribution of puncta depends on the cell shape; as 
can be seen from the randomized distributions that are shifted more to the 
perinuclear region in the spindle-shaped TSC2+/+ MEFs (Figure 23.a., 
Figure 24.a.), than the more circular TSC2-/- MEFs (Figure 23. b., Figure 24. 
b.) and HeLa cells (Figure 23. c., Figure 24. c.). Yet, compared to the 
randomized distributions, most of the PDEδ-Arl2 interaction puncta were 
closer to the nuclear membrane, and became less frequent towards the outer 
regions of the cell in all examined cell types. This demonstrates that PDEδ-
Arl2-GTP interaction preferentially occurs in the perinuclear region of the cell, 
where most of Arl2 is localized. This interaction results in displacement of the 
farnesylated cargo.  
These results combined highlighted the essential role of PDEδ-Arl2GTP 
‘pump’ on maintainance of Rheb localization by binding/localized release of 
farnesylated moiety to/from PDEδ.  
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Figure 23. Arl2 and PDE δ interact in the perinuclear region of the cell 
(a.-c.) Representative maximum intensity projection of a Z-stack depicting PLA interaction puncta between Arl2 and 
PDEδ in TSC2+/+ MEFs (a., n=47 cells), TSC2-null MEFs (b., n=31 cells) and HeLa cells (c., n=35). Graphs: 
Distribution of distances of PLA puncta to the nuclei of the cells. Green: histogram and profile of a calculated random 
distribution, blue: histogram and profile of the measured PLA interaction puncta, black line: nuclear membrane. X-
axis: punctum distance from nuclear center (μm); y-axis: frequency of puncta. P values for individual cells determined 
by Kolmogorov-Smirnov test. P< 0.05: 19/47 cells for a. 24/31 for b. and 35/35 for c. All scale bars=10 μM. 
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Figure 24. PLA analysis in single cells 
(a.-c.) Examples of the analysis of PLA interaction puncta of Arl2 with PDEδ in TSC2+/+ MEF (a.), TSC2-/- MEF (b.) 
and HeLa cells (c.) (see also PLA distribution analysis in Materials and Methods). Left: generated cell mask derived 
from maximal intensity projection where black dots represent PLA interaction puncta in a cell. Blue histogram: 
distribution of puncta relative to the nuclear center, green histogram: random distribution for the representative cell. 
X-axis: punctum distance from nuclear center (μm); y-axis: frequency of puncta. 
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3.4. Cell growth depends on perinuclear release of Rheb-GTP 
from PDEδ  
 
Since PDEδ knockdown resulted in decreased activity of mTORC1 
downstream effectoors in growh-factor responsive cells, we correlated this 
with cell growth and proliferation, processes highly regulated by mTOR.  
For this, we performed impedance-based real-time cell analyzer (RTCA) 
measurements in TSC2+/+ and TSC2-null MEFs with and without PDEδ 
knockout.   
A prominent growth inhibitory effect was observed in TSC2+/+ PDEδ-null 
MEFs (Figure 25.a.). However, the TSC2, PDEδ-null MEFs exhibited a faster 
growth rate than the empty vector control (Figure 25.b.) corroborating the 
tight interaction of Rheb-GTP with mTORC1 that propagates growth signals. 
The reason why the TSC2, PDEδ-null cells grow faster as the parental TCS2 
null cells is likely the increased amount of Rheb-GTP interacting with mTOR 
that cannot get solubilized by PDEδ. 
To evaluate long-term effects of PDEδ knockout on cell growth and 
proliferation, we seeded the same number of TSC2+/+, TSC2+/+ E.V. and 
TSC2+/+ PDEδ-null MEFs, and monitored colony formation over the course of 
10 days (Figure 25.c.). Colony formation completely reflected the RTCA 
growth profiles (Figure 25.d.), where TSC2+/+, PDEδ-null cells generated 
only a few colonies while TSC2, PDEδ-null cells generated significantly more 
colonies as compared to the parental cell lines. These results show that the 
perinuclear concentration of Rheb as maintained by the PDEδ/Arl2 cycle is 
necessary for efficient mTOR engagement and activation of anabolic 
processes in   growth-factor responsive cells.  
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Figure 25. Cell growth depends on perinuclear release of Rheb-GTP from PDEδ  
(a.,b.) Upper panels: Representative RTCA growth profiles of TSC2+/+ MEF (black), TSC2+/+ E.V. MEF (red) and 
TSC2+/+ sgRNA PDEδ MEF (blue) ± s.d. in a. and TSC2-/- MEF (black), TSC2-/- E.V. MEF (red) and TSC2-/- 
sgRNA PDEδ MEF (blue) ± s.d. in b.. Lower panels: Average growth rate ± s.e.m. between 40 and 60 hours from 
three independent experiments of all cell lines with corresponding p values. (c.,d.) Upper panels: Representative 
images of colony formation assay of TSC2+/+ MEF, TSC2+/+ E.V. MEF and TSC2+/+ sgRNA PDEδ MEF in c. and 
TSC2-/- MEF, TSC2-/- E.V. MEF and TSC2-/- sgRNA PDEδ MEF in d.. Cells were seeded at same density and 
grown for 10 days. Lower panels: Graphs represent quantification of area coverage for all cell lines ± s.e.m. based on 
three independent experiments, with corresponding p values. All p values were obtained by unpaired t-test. P values 
>0.05 labeled as not significant (n.s.). 
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4. DISCUSSION 
 
Proper information processing is a complicated, yet necessary network of 
events taking place inside of the cell, responsible for maintaining its identity in 
the ever-changing surrounding environment. The cellular identity in this 
context does not refer to robust response, keeping the cell in one state upon 
one available stimulus, as the type, amount, even the combination of various 
stimuli drives different, fine-tuned responses appropriate for a certain 
condition. Cell growth and protein synthesis are predecessors for other, more 
complicated processes such as proliferation, differentiation, but as well, 
apoptosis. The response to various stimuli, such as growth factors, hormones, 
nutrients, energy and oxygen availability events has a crucial importance to 
maintain cell and organismal homeostasis. All of these inputs converge on a 
single protein kinase, mTOR, whose activation is the final checkpoint in 
driving these processes. mTOR kinase is the most important member of the 
multiprotein complex driving all anabolic processes in the cell. Interestingly, 
although the information from the cellular exterior finds its way to the mTOR 
through a red of different upstream proteins, the only direct activator that 
receives the signals is the small GTPase Rheb. This ubiquitously expressed 
protein has a nucleotide-dependent activating role towards mTOR kinase, as 
the activation and signal propagation occurs only when Rheb is GTP, rather 
than GDP-bound. However, the nucleotide-binding state depends on the 
balance of GAPs and GEFs, proteins that modulate the intrinsic hydrolytic 
state of all GTPases, by promoting the GTP hydrolysis or GTP binding, 
respectively. Small GTPases from a Ras family are included in various signal 
transduction processes activating different protein kinases, and this cycle of 
GDP/GTP binding marks their role as a ‘molecular switch’, as those 
processes are driven by their ‘on’ (GTP-bound) or ‘off’ (GDP-bound) state. 
Rheb differs from the other members of the Ras family as it is found in a very 
high activation state in the cells, even in those deprived of growth factors or 
nutrients. This implies two ways of regulation: either mTOR is constantly 
active, or the activity state of Rheb is depends mostly on negative regulation, 
through GAP. The latter one is more likely, as the permanent activation of cell 
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growth and protein synthesis are not sustainable solutions in cells that need to 
sense changes in the environment and accordingly formulate the strategy for 
response. The high activation state of Rheb implied that the GEF for it is not 
necessary, and that its activity is modulated purely by its GAP, TSC. In the 
absence of activating stimuli, TSC2 (member of the complex with the GAP 
domain) localizes to the lysosomes, where the reported interaction between 
Rheb-GTP and mTOR takes place. Growth factor or hormonal availability 
relocalizes TSC2 to the cytoplasm, which is additionally phosphorylated at 
different sites through PI3K/Akt action, resulting in its inactivation. Therefore, 
Rheb activity and mTOR activation are modulated by spatial segregation of 
active TSC2. 
Rheb is an endomembrane bound protein, which undergoes irreversible 
posttranslational modification, farnesylation, and displays a high perinuclear 
concentration. It was reported that these characteristics are necessary for its 
signaling activity, however, why this is the case, it is unknown.  
Additionally, Rheb binds to PDEδ, a GDI-like solubilizing factor for 
farnesylated Ras proteins, whose role was proven to be essential in 
maintaining their localization. Through Arl2-GTP mediated localized release, it 
was reported that K-Ras gets electrostatically trapped on the recycling 
endosome, from where its plasma-membrane association is reinstated by 
vesicular transport. However, role of Arl2-GTP mediated release from PDEδ 
in maintaining localization of Rheb, and in turn its signaling activity, is still 
unknown. The main aim of this thesis was to address the question of 
regulating spatial organization of Rheb, and to investigate in depth how this 
localization affects its signaling ability. Additional aim was to uncover the role 
of PDEδ/Arl2-GTP mediated spatial cycle and confirm its suspected function 
as a universal mechanism for maintaining localization of all farnesylated 
proteins. Finally, by using a model for aberrant mTOR signaling (TSC2-null 
MEFs), we uncovered the coupling of GTPase and spatial cycle of Rheb. 
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4.1. Arl2-GTP mediated localized release of farnesylated cargo 
from PDEδ maintains localization of Ras proteins 
 
Prenyl binding factors have been shown to assist in intracellular trafficking of 
various Ras isoforms. PDEδ was identified as a solubilizing factor of small G 
proteins from the Ras family, by enhancing their effective diffusion in the 
cellular cytosol (Chandra et al. 2012). Enhanced kinetics of prenylated Ras 
proteins, mediated by a cytosolic chaperone, counters their tendencies to 
equilibrate on all membranes. Both Arf-like proteins, Arl2 and Arl3, were 
shown to interact with PDEδ in a GTP-dependent manner (Ismail et al. 2011; 
Linari, Hanzal-Bayer, and Becker 1999). Arl2 was shown to be an allosteric 
displacement factor for low-affinity farnesylated cargo (K-Ras or Rheb) from 
PDEδ both, in vitro and in vivo (Schmick et al. 2014; Ismail et al. 2011; 
Linari, Hanzal-Bayer, and Becker 1999; Fansa et al. 2016)). On the other 
hand, Arl3 has a prominent role in releasing high-affinity farnesylated cargo 
(inositol polyphosphate-5-phosphatase E; INPP5E) from PDEδ in primary cilia 
of cells. However, although Arl3 can release low-affinity cargo from PDEδ in 
vitro (K-Ras or Rheb), it does not seem to have this role in vivo (Fansa et al. 
2016), as the knockdown of Arl2 alone was sufficient to mislocalize K-Ras 
(Schmick et al. 2014). We have shown that only Arl2 knockdown results in 
mislocalization of Rheb, corroborating its prominent role in release of 
farnesylated cargo. 
It was shown that the Arl2-GTP mediated release from PDEδ must be 
localized in cells in order to maintain the K-Ras out-of-equilibrium plasma 
membrane localization. Interestingly, this localized release was not confirmed 
at the plasma membrane, but the likely site was perinuclear region of the cell. 
It was corroborated that perinuclear area of the cell is where the active form of 
Arl2 is present, however, due to technical limitations (overexpressed 
proteins), it was not shown directly (Schmick et al. 2014).  
Proximity ligation assay is an antibody-based assay that depicts interaction of 
two or more proteins in the cell on endogenous level (Soderberg et al. 2006). 
The interaction punctae for Arl2 and PDEδ were prominent in the perinuclear 
region of the cell, compared to the rest. It indeed showed that the perinuclear 
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area is the location of Arl2-GTP and PDEδ interaction, which results in 
displacement of farnesylated cargo. Since Rheb does not reside on 
organelles exhibiting vesicular transport, it does not accumulate on the 
plasma membrane. However, the typical perinuclear enrichment it does 
display could be explained through its displacement from PDEδ via Arl2-GTP 
activity. Upon treatment with small-molecule PDEδ inhibitor, Deltarasin, both 
mCherry-Rheb and mCitrine-Rheb HVR have shown the reduced perinuclear 
accumulation. The fact that mCitrine-Rheb HVR showed perinuclear 
enrichment pointed additionally that the site of Arl2-GTP mediated release of 
farnesylated cargo from PDEδ is in this cellular region. Treatment with 
Deltarasin resulted in decreased enrichment, showing that solubilization 
through PDEδ is necessary for its maintainance. Altogether, these results 
demonstrated that spatial cycles mediated by Arl2-GTP and PDEδ represent 
a universal mechanism, which by countering equilibration tendencies of 
farnesylated Ras proteins maintains their out-of-equilibrium localization, 
important for their signaling output.  
4.2. Perinuclear Rheb concentration depends on the activity 
state of Rheb 
G domain of small GTPases is the locus of nucleotide binding, GTP-
hydrolysis and effector binding. It is a part of the protein that determines its 
activity (Wittinghofer and Vetter 2011). It was reported however, that a C-
terminal farnesylated part of the protein responsible for membrane binding, is 
essential for maintaining its signaling activity (Clark et al. 1997; Buerger, 
DeVries, and Stambolic 2006). 
We have uncovered that the interaction between PDEδ and Arl2-GTP is the 
basis for maintainance of perinuclear localization of Rheb. Both PDEδ 
knockout and Arl2 knockdown resulted in mislocalization of Rheb, in two 
different ways: loss of PDEδ resulted in relocalization on all membranes, while 
loss of Arl2 in increased soluble fraction of Rheb. Since this effect was only 
visible in TSC2+/+ MEFs, but not in TSC2-null MEFs, this implied that the 
activity state of Rheb is coupled to generation of this out-of-equilibrium 
localization. 
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Unlike all the other small GTPases, where both the interaction and the 
activation of their respective effectors depend on their GTP-binding, Rheb 
interacts with mTOR in both GDP and GTP bound state (Long et al. 2005; 
Smith et al. 2005). However, the activation of mTOR occurs only when it is in 
GTP bound state.  
It was reported than amino acid withdrawal inhibits the interaction between 
Rheb and mTOR (Sancak et al. 2010; Bar-Peled et al. 2012). Upon amino 
acid withdrawal, mTOR relocalizes to the cytosol, while Rag GTPases recruit 
TSC2 to the lysosome, which inactivates Rheb (Demetriades, Doumpas, 
and Teleman 2014). However, it is known that the TSC2 is inactivating Rheb 
in the absence of other activating stimuli as well, and that it is active at the 
lysosome, where it hydrolyzes active Rheb (Demetriades, Plescher, and 
Teleman 2016). Since the perinuclear concentration of mCitrine-Rheb HVR 
decreased in both TSC2+/+ and TSC2-null sgRNA PDEδ cells, while it 
remained unchanged in the same cells expressing constitutively active 
mCitrine-Rheb Q64L, we corroborated that even if the interaction between 
mTOR and Rheb exists in the GDP bound state; the binding affinity of Rheb 
GTP-mTOR complex is higher than Rheb GDP-mTOR. Since TSC2-null cells 
possess constitutively active Rheb, we could only presume that lack of any 
effect on Rheb localization upon disruption of PDEδ/Arl2 cycle is due to the 
tight interaction of Rheb-GTP with mTOR, which impairs resolubilization of 
Rheb and new entrance to the spatial cycle. 
4.3. TSC2 GAP activity determines the localization of Rheb 	
It was reported that the activation of mTORC1 relies on two aspects: 
activation of Rheb as a result of various upstream stimuli and proper mTOR 
localization (Guertin and Sabatini 2007). Both of these aspects are 
determined by the activity of the Rheb GAP TSC2. It was widely regarded that 
the phosphorylation of TSC2 on different residues through Akt completely 
deactivates it; therefore, Rheb can bind GTP (Cai et al. 2006). However, in 
vitro studies have suggested that its GAP activity is largely intact upon Akt 
phosphorylation, suggesting a different mechanism of its activation (Menon et 
al. 2014). It was reported that depending on the growth factor and amino acid 
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availability TSC2 translocates to/from the lysosomes where it promotes GTP-
hydrolysis on Rheb and blocks mTOR kinase (Demetriades, Doumpas, and 
Teleman 2014). Studies concerning the interaction between Rheb and mTOR 
have all led to different conclusions. One study reported that the interaction 
does not depend on the nucleotide-bound state, and that it was stronger with 
mutants that exist in GDP bound form (Long et al. 2005). However, studies 
made in yeast have shown that the interaction is indeed preferential with GTP 
bound form (Urano et al. 2001). Additionally, since it has been challenging to 
find Rheb associated with mTORC1 upon in vitro incubation, additional 
hypothesis arose claiming that the interaction between the two is transient 
and loose (Parmar and Tamanoi 2010). We have shown that nucleotide-
binding state of Rheb affects its localization as in cells with constitutively 
active Rheb its perinuclear concentration was significantly higher compared to 
cells responsive to growth factors. Since various expression levels of PDEδ 
had no effect on solubilizing this active Rheb, our presumption is that this 
Rheb is contained in the perinuclear region, presumably through interaction 
with mTOR, which is tighter in case of GTP-bound Rheb.  
This implies that once the GTPase cycle (GTP/GDP exchange) of Rheb is 
stopped, and Rheb is locked in the active state, due to the presence of stimuli 
or mutation, this interaction with mTOR impairs resolubilization and stalls the 
PDEδ/Arl2 spatial cycle as well.  
4.4. mTOR signaling activity relies on perinuclear Rheb 
concentration 
 
Spatial cycle of all Ras proteins relies on the posttranslational farnesylation 
and the ability of PDEδ to solubilize these proteins in the cytosol (Chandra et 
al. 2012; Schmick et al. 2014; Schmick, Kraemer, and Bastiaens 2015). 
Responsiveness to growth factors, a trait necessary for activation of Rheb and 
proper mTORC1 regulation, proved to be coupled to the spatial cycle. PDEδ 
and Arl2 localization of Rheb was already disrupted upon interference with its 
spatial cycle, however, only in growth-factor responsive cells. Signal 
propagation through mTOR kinase relies on its binding to active, GTP-bound 
Rheb. The phosphorylation of downstream effector S6 was lower than the 
	 96	
control only in growth factor responsive cells, but not in cells with 
constitutively active Rheb, where it remained unchanged. TSC2+/+ cells 
responded to insulin stimulation as well, visible in up regulation of 
phosphorylation of S6, even the cells with PDEδ knockout. This implies that 
the spatial cycle is not necessary to maintain responsiveness to growth 
factors. However, it was reported that mice with an inhibited or downregulated 
mTORC1 signaling have a lower body weight, liver, and that this has lethal 
consequences (Polak et al. 2008; Guridi et al. 2016). Therefore, to maintain 
the cellular homeostasis, the spatial cycle is necessary to generate a 
sufficient pool of Rheb to be activated and interact with mTOR.  
Cell growth and cell proliferation are two complex processes regulated 
through a plethora of activating signals coming from the extracellular 
environment. mTOR is the main regulator of cell growth; therefore, impairing 
its proper activation would have an inhibitory effect on this process.   
Colony formation assay and RTCA growth curves have shown that the 
prominent inhibitory effect on cell growth was only visible in TSC2+/+ MEFs 
with PDEδ knockout. This confirmed the hypothesis that the spatial cycle 
mediated by PDEδ and Arl2-GTP is necessary to generate sufficient amount 
of growth factor-responsive Rheb in the perinuclear area to activate mTOR. 
Interestingly, TSC2-null sgRNA PDEδ MEFs have displayed even a higher 
rate of growth and colony formation compared to their control. This was in line 
with the hypothesis that the interaction between mTOR and Rheb-GTP is 
stable and this Rheb does not dissociate as high as Rheb-GDP, therefore the 
spatial cycle is stalled. However, in cells with PDEδ knockout, this is even 
more efficient, as there is no loss to cytosol.  
Still, it is known that PI3K/Akt/mTOR and Ras/Erk signaling axis have a lot of 
intersecting points, enabling crosstalk (Mendoza, Er, and Blenis 2011). In 
order to confirm whether this effect is attributed to the enhanced mTOR 
activity, the levels of Akt, Erk and other kinases known to intersect with mTOR 
signaling axis should be monitored in order to confirm that positive growth 
effect can be attributed to mTOR signaling specifically.  
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4.5. PDEδ-mediated solibilization is necessary for nucleotide 
exchange on Rheb 
 
Rheb has been found in unusually high activation state in cells, however 
guanine nucleotide exchange factors have not yet been identified, and their 
necessity for guanine nucleotide exchange on Rheb is still not clear (Im et al. 
2002; Inoki et al. 2003). It was reported that the intrinsic nucleotide exchange 
rate of Rheb is markedly higher in solution than upon association with a 
bilayer membrane (Mazhab-Jafari et al. 2013), which indicates that soluble 
Rheb will exchange GDP more quickly to GTP, which is in high excess in 
cells. In addition, it was reported that Rheb has a higher affinity to bind GTP 
than GDP (Patel et al. 2003), and unlike other GTPases, it possesses an auto 
inhibited mechanism of GTP-hydrolysis, favoring the GTP-bound state in the 
absence of GAP activity (Mazhab-Jafari et al. 2012). In the absence of 
upstream stimuli, this GAP activity is present only on the perinuclear 
lysosomal membranes (Demetriades, Doumpas, and Teleman 2014; 
Menon et al. 2014; Demetriades, Plescher, and Teleman 2016), allowing 
for nucleotide exchange on Rheb localized outside this area. Solely 
farnesylated proteins have a high partitioning rate from membranes to the 
cytosol (2:1) (Schmick et al. 2014). Therefore, a very high proportion of Rheb 
is available to bind to PDEδ and be in a soluble state, which favors GTP-
binding. This passive process of PDEδ binding to prenylated Ras proteins 
occurs regardless of their GDP/GTP-bound state. However, for Rheb, 
solubilization as well results in its removal from the perinuclear-membrane 
associated TSC2 GAP activity. This promotes exchange of the bound guanine 
nucleotide to GTP in the cytosol. Therefore, solubilization mediated by PDEδ 
is a necessary step not only for concentrating Rheb-GTP at the perinuclear 
membranes via Arl2-GTP activity, but as well in direct promotion of its GTP-
binding. This coupling of the generic activity of the PDEδ/Arl2-GTP 
mechanism to a stimulus-dependent localization of regulatory protein TSC2 
enables tunable signal transduction mediated by Rheb and promotion of 
anabolic processes. 
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4.6. Spatial cycle of Rheb is coupled to its GTPase cycle 
 
Rheb is farnesylated Ras protein associating with endomembranes. Due to 
lack of an additional targeting sequence that would associate it with specific 
membrane compartments, as a solely farnesylated protein it displays a high 
partitioning rate between endomembranes and the cytosol. In the cytosol, it is 
sequestered by a GDI-like solubilizing factor PDEδ, which possesses a 
hydrophobic binding pocket for prenylated proteins. This complex has a high 
effective diffusion speed and explores intracellular space on a faster rate than 
Rheb alone. Once it reaches perinucelar area, Arl2-GTP, by binding to PDEδ, 
causes a conformational change that places hydrophobic pocket in the closed 
state, initiating displacement of Rheb on the perinuclear membranes. Both 
Rheb GAP, TSC2 and effector mTOR reside in this region. When cells are 
deprived of growth factors or hormones, TSC2 promotes GTP hydrolysis on 
Rheb, disabling perinuclear Rheb from activating mTOR. This results in Rheb 
dissociation from these membranes and subsequent resolubilization by PDEδ. 
Since it is spatially segregated from its GAP, Rheb in the cytosol binds GTP, 
which is in high excess in cells, and reenters the spatial/GTPase cycle. When 
the cells are stimulated with growth factors, TSC2 is phosphorylated through 
Akt, and relocalizes from the perinuclear region to the cytosol. Therefore, 
Rheb-GTP, released from PDEδ through local Arl2-GTP activity can now bind 
to and activate mTOR, resulting in signal propagation to downstream 
effectors. As a consequence of this interaction, the spatial cycle, mediated by 
PDEδ and Arl2-GTP is stalled, as Rheb-GTP is stabilized on the perinuclear 
membranes through interaction with mTOR and does not dissociate 
significantly from the perinuclear membranes (Figure 26).  
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Figure 23. Coupling of GTPase cycle and spatial cycle of Rheb 
Model explaining coupling of GTPase and spatial cycle of Rheb. a. Soluble GTP-bound Rheb is bound to PDEδ.. 
Once  the complex reaches perinuclear area of the cell,  the allosteric displacement factor for farnesylated cargo, 
Arl2-GTP, binds to PDEδ, resulting in release of farnesylated cargo on perinuclear membranes, including the 
lysosome. Here, TSC2 hydrolyzes GTP bound to Rheb, and GDP-Rheb, unable to ind and activate mTOR, 
dissociates from perinuclear membranes to the cytosol, where it can exchange GDP to GTP and get reactivated. b. 
Presence of growth factors inactivates TSC2, therefore, active Rheb on perinucelar membranes, delivered by 
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PDEδ/Arl2-GTP activity, can bind to and activate mTOR: This results in decreased dissociation from the perinucelar 
membranes, effectively stopping spatial cycle.  
 
4.6. Conclusion 
 
The work in this thesis focuses on two mechanistically different processes 
that, by their coupling, enable the protein to exert its functional role in the cell. 
GTPase cycles determine the activity of G-proteins, but as well the activity of 
the entire signaling axis in which these proteins are placed. Through their 
proper regulation, the specificity, tunability and response to environmental 
signals are enabled.  
Spatial cycles are a way of countering entropic tendencies of proteins, arising 
from their structure, which would result in diluted and inefficient signal 
propagation.  
The intersection of the generic spatial mechanism and specific activity cycle of 
GTPase represents a unique mechanism for function of small GTPase Rheb 
and its effector mTORC1. We have shown that the role of solubilizing factor 
PDEδ is crucial in this particular system, not only as a factor responsible for 
countering equilibration on all membranes, but as well as an effective “GEF”, 
promoting efficient nucleotide exchange Rheb. It represents the rate-limiting 
factor in the entire spatial cycle of Rheb, as its loss results in significant 
decrease in mTORC1 activity and mislocalization of Rheb.  
However, non-functional GTPase cycle impairs the importance of the spatial 
cycle: if Rheb is permanently GDP-loaded, the spatial cycle is futile, as it 
cannot exert its function towards mTOR. If Rheb is GTP-loaded, the spatial 
cycle is halted, due to low dissociation of Rheb from membranes, which 
results in permanent mTOR activation.  
We have shown that regulated GTPase cycle of Rheb, coupled to its spatial 
cycle enables sensing of the environment through the mTORC1-signaling 
axis, which results in controlled cellular response. 
This coupling allows the cells to sustain a basal level of anabolic processes 
occurring, and maintains its homeostasis.  
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